

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/31, A61K 39/02, 39/106		A1	(11) International Publication Number: WO 97/20050
			(43) International Publication Date: 5 June 1997 (05.06.97)
(21) International Application Number: PCT/AU96/00767		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 29 November 1996 (29.11.96)		<p>Published With international search report.</p>	
(30) Priority Data: PN 6910 30 November 1995 (30.11.95) AU PN 6911 30 November 1995 (30.11.95) AU			
(71) Applicants (for all designated States except US): DARATECH PTY. LTD. [AU/AU]; 3rd floor, 493 St. Kilda Road, Melbourne, VIC 3004 (AU). PIG RESEARCH AND DEVELOPMENT CORPORATION [AU/AU]; Industry House, 3rd floor, Brisbane Avenue, Barton, ACT 2600 (AU).			
(72) Inventors; and (75) Inventors/Applicants (for US only): PANACCIO, Michael [AU/AU]; 122 Hill Road, North Balwyn, VIC 3104 (AU). HASSE, Detlef [AU/AU]; 4 Scullin Court, Sunbury, VIC 3429 (AU).			
(74) Agents: HUGHES, E., John, L. et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, VIC 3000 (AU).			
(54) Title: THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS			
(57) Abstract			
<p>The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by <i>Lawsonia intracellularis</i> or similar or otherwise related microorganism. The present invention also contemplates methods for the treatment and/or prophylaxis of such intestinal disease conditions and to diagnostic agents and procedures for detecting <i>Lawsonia intracellularis</i> or similar or otherwise related microorganism.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SG	Singapore
CI	Côte d'Ivoire	LI	Liechtenstein	SI	Slovenia
CM	Cameroon	LK	Sri Lanka	SK	Slovakia
CN	China	LR	Liberia	SN	Senegal
CS	Czechoslovakia	LT	Lithuania	SZ	Swaziland
CZ	Czech Republic	LU	Luxembourg	TD	Chad
DE	Germany	LV	Latvia	TG	Togo
DK	Denmark	MC	Monaco	TJ	Tajikistan
EE	Estonia	MD	Republic of Moldova	TT	Trinidad and Tobago
ES	Spain	MG	Madagascar	UA	Ukraine
FI	Finland	ML	Mali	UG	Uganda
FR	France	MN	Mongolia	US	United States of America
GA	Gabon	MR	Mauritania	UZ	Uzbekistan
				VN	Viet Nam

- 1 -

## THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS

The present invention relates generally to therapeutic compositions for the treatment and/or  
5 prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by  
*Lawsonia intracellularis* or similar or otherwise related microorganism. The present invention  
also contemplates methods for the treatment and/or prophylaxis of such intestinal disease  
conditions and to diagnostic agents and procedures for detecting *Lawsonia intracellularis* or  
similar or otherwise related microorganism.

10

Bibliographic details of the publications numerically referred to in this specification are  
collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the  
nucleotide and amino acid sequences referred to in the specification are defined following the  
bibliography.

15

Throughout this specification, unless the context requires otherwise, the word "comprise", or  
variations such as "comprises" or "comprising", will be understood to imply the inclusion of  
a stated element or integer or group of elements or integers but not the exclusion of any other  
element or integer or group of elements or integers.

20

The meat industry in Australia and, indeed, in most countries of the world, is an important  
aspect of the overall livestock industry. However, the meat industry is subject to rapid  
economic downturn in response to disease conditions affecting the animals as well as human  
diseases putatively carried by the animals. It is important, therefore, to have well defined  
25 treatment, prophylactic and diagnostic procedures available to deal with infections or potential  
infections in animals and humans.

Pigs form a major component of the meat industry. However, pigs are sensitive to a wide  
spectrum of intestinal diseases collectively referred to as porcine proliferative enteropathy  
30 (PPE). This disease has previously been known as intestinal adenomatosis complex (1),

- 2 -

porcine intestinal adenomatosis (PIA), necrotic enteritis (2), proliferative haemorrhagic enteropathy (3), regional ileitis (4), haemorrhagic bowel syndrome (5), porcine proliferative enteritis and *Campylobacter* spp induced enteritis (6).

5 There are two main forms of PPE: a non-haemorrhagic form represented by intestinal adenomatosis which frequently causes growth retardation and mild diarrhoea; and a haemorrhagic form, which is often fatal, represented by proliferative haemorrhagic enteropathy (PHE) where the distal small intestine lumen becomes engorged with blood. PPE has been reported in a number of animal species including pigs (14), hamsters (7), ferrets (15), guinea  
10 pigs (16), rabbits (17) as well as avian species (18).

The causative organism of PPE is a *Campylobacter*-like organism referred to herein as "*Lawsonia intracellularis*" (26). The organism has also been previously referred to as *Ileal symbiont intracellularis* (7). PPE-like diseases in pigs may also be caused by other pathogens  
15 such as various species of *Campylobacter* (8).

*Lawsonia intracellularis* is an intracellular, possibly obligate intracellular, bacterium. It can only be cultured *in vitro* with tissue culture cells (9, 26). Pigs suffering from PPE are characterised by multiple abnormal immature crypts and *L. intracellularis* is located in the  
20 cytoplasm of these crypt cells.

PPE is a significant cost component associated with the pig industry, especially in terms of stock losses, medication costs, reduced growth rates of pigs and increased feed costs. PPE also contributes to downstream indirect costs in, for example, additional labour costs and  
25 environmental costs in dealing with antibiotic residue contamination and in control measures to prevent the organism being passed on or carried to other animals or humans.

Current control strategies for PPE rely on the use of antibiotics. However, such a strategy is considered to be short to medium term especially as governmental regulatory pressures tend to  
30 target animal husbandry practices which are only supported by prophylactic antibiotics. There

- 3 -

is a need, therefore, to develop effective, safe and low cost alternatives to the use of antibiotics. There is also a need to extend this alternative to antibiotics to similar organisms which infect other animals such as humans.

- 5 In work leading up to the present invention, the inventors sought to develop vaccines for the prophylaxis and treatment of PPE in animals and birds. The vaccines of the present invention provide an efficacious alternative to the use of antibiotics with a range of consequential husbandry and medical benefits.
- 10 Accordingly, one aspect of the present invention provides a vaccine composition for the prophylaxis or treatment of infection in an animal or bird by *L. intracellularis* or similar or otherwise related microorganism, said vaccine composition ~~comprising an immunogenic~~, non-pathogenic form of *L. intracellularis* or related microorganism or an immunogenic component thereof and one or more carriers, diluents and/or adjuvants suitable for veterinary or  
15 pharmaceutical use.

The present invention is particularly useful and is exemplified hereinafter in relation to the protection and/or treatment of pigs from infection with *L. intracellularis*. However, this is done with the understanding that the present invention extends to the prophylaxis and treatment of  
20 all animals including humans and birds from infection with *L. intracellularis* and/or related microorganisms. Animals contemplated by the present invention include but are not limited to humans, primates, companion animals (e.g. cats, dogs), livestock animals (e.g. pigs, sheep, cattle, horses, donkeys, goats), laboratory test animals (e.g. mice, rats, guinea pigs, rabbits) and captive wild animals (e.g. kangaroos, foxes, deer). The present invention also extends to birds  
25 such as poultry birds, game birds and caged birds.

Furthermore, the present invention extends to all isolates and sub-types of *L. intracellularis* as well as other species of the genus *Lawsonia* or other microorganisms related thereto at the nucleotide, biochemical, structural, physiological and/or immunointeractive level. Reference  
30 hereinafter to "*Lawsonia intracellularis*" or its abbreviation "*L. intracellularis*" includes all

microorganisms similar to or otherwise related to this microorganism. For example, a related microorganism may have a nucleotide sequence similarity at the chromosome or extrachromosomal level of at least about 60%, more preferably at least about 70% and even more preferably greater than at least about 80% with respect to all or part of a nucleotide sequence within the chromosome or extrachromosomal elements of *L. intracellularis*. For example, these percentage similarities may relate to the sequence set forth in SEQ ID NO:5. This sequence is a portion of the *L. intracellularis* chromosome.

Accordingly, this aspect of the present invention is directed to a vaccine composition for the prophylaxis and/or treatment of infection in a pig by *L. intracellularis*, said vaccine composition comprising an immunogenic, non-pathogenic form of *L. intracellularis* or related microorganism or an immunogenic component thereof and one or more carriers, diluents and/or adjuvants suitable for veterinary or pharmaceutical use.

The term "immunogenic component" refers to *L. intracellularis* (in attenuated non-pathogenic or killed form) or a component of *L. intracellularis* including a peptide, polypeptide or a protein encoded by DNA from or derived from *L. intracellularis* which is capable of inducing a protective immune response in a pig. A protective immune response may be at the humoral and/or cellular level and generally results in a substantial reduction in the symptoms of PPE in pigs. The vaccine compositions will comprise an effective amount of immunogenic component such as to permit induction of a protective immune response.

According to this aspect of the present invention there is provided a vaccine composition for the prophylaxis and treatment of a pig by *L. intracellularis*, said vaccine composition comprising an amount of at least one immunogenic component from *L. intracellularis* or related microorganism effective to induce a protective immune response in said pig against *L. intracellularis* or related microorganism, said vaccine composition further comprising one or more carriers, adjuvants and/or diluents suitable for veterinary or pharmaceutical use.

The immunogenic component may be a naturally occurring peptide, polypeptide or protein, a



- 5 -

carbohydrate, lipid or nucleic acid (e.g. DNA) or any combination thereof isolated from *L. intracellularis* or a cell culture thereof or a recombinant form of a peptide, polypeptide or protein encoded by DNA from or derived from *L. intracellularis* or is a derivative of said peptide, polypeptide or protein.

5

An isolated component of *L. intracellularis* is a component which has undergone at least one purification step or which has undergone at least partial concentration from a cell culture comprising *L. intracellularis* or from a lysed preparation of *L. intracellularis* cells. The purity of such a component from *L. intracellularis* which has the requisite immunogenic properties  
10 is preferably at least about 40%, more preferably at least about 50%, even more preferably at least about 60%, still more preferably at least about 70% and even more preferably at least about 80-90% or greater relative to other components in a preparation as determined by molecular weight, immunogenic activity or other suitable means.

15 A particularly useful form of the vaccine is a whole cell vaccine which comprises *L. intracellularis* in attenuated or otherwise non-pathogenic form or killed cells or various fractions thereof.

Attenuated or non-pathogenic cells include killed *L. intracellularis* cells prepared, for example,  
20 by heat, formalin or other chemical treatment, electric shock or pressure and such cells are particularly useful in the practice of the present invention.

According to this aspect of the present invention there is provided a vaccine composition for the prophylaxis and/or treatment of infection in a pig by *L. intracellularis* or related  
25 microorganism said vaccine composition comprising a killed preparation of *L. intracellularis* or related microorganism or an immunogenic fraction thereof and one or more carriers, diluents and/or adjuvants suitable for veterinary or pharmaceutical use.

In an alternative embodiment, a recombinant vaccine may be employed. The recombinant  
30 vaccine may comprise one or more recombinant peptides, polypeptides or proteins derived from

- 6 -

*L. intracellularis* or is a recombinant molecule immunologically related to a peptide, polypeptide or protein derived from *L. intracellularis* or may be a fusion molecule having a first portion comprising a peptide, polypeptide or protein derived from *L. intracellularis* and a second heterologous peptide, polypeptide or protein which may be useful, for example, as a carrier molecule or an adjuvant or an immune stimulating molecule such as cytokine. A particularly useful recombinant protein from *L. intracellularis* comprises a peptide, polypeptide or protein derived from the cell surface or membrane of *L. intracellularis*, is an enzyme in a metabolic pathway within *L. intracellularis* or is a refolding and/or heatshock protein. In a preferred embodiment, the protein is a refolding/heatshock protein such as but not limited to GroEL and GroES. Other putative vaccine candidates include flagellar basal body rod protein, S-adenosylmethionine: tRNA ribosyltransferase-isomerase, enoyl-(acyl-carrier-protein) reductase, N-acetyl muramoyl-L-alanine amidase (autolysin), UOP-3-0-[3-hydroxymyristoyl] glucosamine N-acetyltransferase and a glucarate transporter.

According to a preferred embodiment, the present invention relates to a vaccine composition for the prophylaxis and/or treatment of infection in a pig by *L. intracellularis* or related microorganism, said vaccine composition comprising at least one recombinant peptide, polypeptide or protein from *L. intracellularis* and wherein said recombinant peptide, polypeptide or protein is capable of inducing a protective immune response against *L. intracellularis* in pigs, the vaccine composition further comprising one or more carriers, diluents and/or adjuvants suitable for veterinary or pharmaceutical use.

In a particularly preferred embodiment, the recombinant protein is GroEL having an amino acid sequence as set forth in SEQ ID NO:2 or is a protein having a predicted amino acid sequence with at least about 40%, at least about 60%, or more preferably at least about 70% and even more preferably at least about 80-90% or greater similarity to all or part of the amino acid sequence set forth in SEQ ID NO:2.

In another embodiment, the recombinant molecule is GroES having an amino acid sequence as set forth in SEQ ID NO:4 or is a molecule having an amino acid sequence at least about 40%,

- 7 -

at least about 60%, more preferably at least about 70% and even more preferably at least about 80-90% or greater similarity to all or part of the amino acid sequence set forth in SEQ ID NO:4.

Another embodiment of the present invention includes and comprises a peptide, polypeptide  
5 or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:1 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

10 In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:3 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

15

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:5 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
20 microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:6 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
25 which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:8 or having at least  
30 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and

which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
5 or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:11 or having at least  
40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
microorganism.

10 In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:13 or having at least  
40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
microorganism.

15 In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:15 or having at least  
40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
20 microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:17 or having at least  
40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
25 which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:18 or having at least  
30 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and

which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide  
5 or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:19 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

10 In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:20 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

15

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:21 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related  
20 microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:22 or having at least 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and  
25 which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

In a related embodiment, the present invention includes and comprises a peptide, polypeptide or protein encoded by a nucleotide sequence as set forth in SEQ ID NO:23 or having at least  
30 40% similarity thereto or capable of hybridizing thereto under low stringency conditions and

- 10 -

which nucleotide sequence encodes an immunogenic component of *L. intracellularis* or related microorganism.

Preferred percentage similarities include at least about 50% or at least about 60% or at least about 70-90%.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.

10 Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and

15 from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

The present invention also contemplates peptides, polypeptides or proteins having an amino acid sequence substantially as set forth in one of SEQ ID NO:7 or 9 or 10 or 12 or 14 or 16 or

20 having at least 40% similarity thereof or to all or part thereof. Preferred percentage similarities include at least about 50%, or at least about 60% or at least about 70-90%.

The present invention further extends to a vaccine comprising a recombinant vaccine vector encoding a peptide, polypeptide or protein derived from *L. intracellularis* or related

25 microorganism as described above. The vaccine vector may be of viral, yeast or bacterial origin and would be capable of expression of a genetic sequence encoding a peptide, polypeptide or protein from *L. intracellularis* in a manner effective to induce a protective immune response. For example, a non-pathogenic bacterium could be prepared containing a recombinant sequence capable of encoding a peptide, polypeptide or protein from *L. intracellularis*. The recombinant

30 sequence would be in the form of an expression vector under the control of a constitutive or

- 11 -

inducible promoter. The bacterium would then be permitted to colonise suitable locations in a pig's gut and would be permitted to grow and produce the recombinant peptide, polypeptide or protein in amount sufficient to induce a protective immune response against *L. intracellularis*.

5

In a further alternative embodiment, the vaccine may be a DNA vaccine comprising a DNA molecule encoding a peptide, polypeptide or protein from *L. intracellularis* and which is injected into muscular tissue or other suitable tissue in a pig under conditions sufficient to permit transient expression of said DNA to produce an amount of peptide, polypeptide or  
10 protein effective to induce a protective immune response.

The vaccines of the present invention may contain a single peptide, polypeptide or protein or a range of peptides, polypeptides or proteins covering different or similar epitopes. In addition, or alternatively, a single polypeptide may be provided with multiple epitopes. The latter type  
15 of vaccine is referred to as a polyvalent vaccine. A multiple epitope includes two or more repeating epitopes.

The formation of vaccines is generally known in the art and reference can conveniently be made to Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pennsylvania,  
20 USA.

The present invention, therefore, contemplates a pharmaceutical composition or vaccine composition comprising an immunity developing effective amount of one or more of:

- 25 (i) an immunogenic component from *L. intracellularis*;  
(ii) a recombinant peptide, polypeptide or protein from *L. intracellularis* having immunogenic properties; and/or  
(iii) whole cells or a component or fraction thereof from *L. intracellularis*.

30 The above components are referred to hereinafter as "active ingredients". The active

ingredients of a vaccine composition as contemplated herein exhibit excellent therapeutic activity, for example, in the treatment and/or prophylaxis of PPE when administered in an amount which depends on the particular case. For example, for recombinant molecules, from about 0.5  $\mu$ g to about 20 mg may be administered. Other useful effective amounts include 1  $\mu$ g to about 10 mg, 10  $\mu$ g to about 5 mg and 50  $\mu$ g to about 1 mg. The important feature is to administer sufficient to induce an effective protective immune response. The above amounts may be administered as stated or may be calculated per kilogram of body weight. Dosage regime may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. Booster administration may also be required.

The active ingredients may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (eg using slow release technology). Depending on the route of administration, the active ingredients which comprise, for example, peptides, polypeptides or proteins may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients.

The term "adjuvant" is used in its broadest sense and includes any immune stimulating compound such as interferon. Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether and Freund's complete and incomplete adjuvant.

The active compounds may also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile



injectable solutions or dispersion. In all cases the form must be fluid to the extent that easy syringability exists unless the pharmaceutical form is a solid or semi-solid such as when slow release technology is employed. In any event, it must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of  
5 microorganisms.

The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof and vegetable oils. The proper fluidity can be maintained, for  
10 example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride.  
15 Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as  
20 required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a  
25 powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

Carriers and diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media  
30 and agents in vaccines is well known in the art. Except insofar as any conventional media or

agent is incompatible with an active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

- 5 Still another aspect of the present invention is directed to antibodies to the peptides, polypeptides or proteins from *L. intracellularis* or recombinant forms thereof or non-proteinaceous molecules such as carbohydrates. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to *L. intracellularis* or may be specifically raised to specific molecules or whole cells or components or fractions thereof.
- 10 The antibodies of the present invention are particularly useful for immunotherapy and vaccination and may also be used as a diagnostic tool for infection or for monitoring the progress of a vaccination or therapeutic regime.

For example, recombinant *L. intracellularis* peptides, polypeptides or proteins can be used to  
15 screen for naturally occurring antibodies to *L. intracellularis*. Alternatively, specific antibodies can be used to screen for *L. intracellularis*. Techniques for such assays are well known in the art and include, for example, sandwich assays and ELISA. Hereinafter, an immunogenic component is considered to encompass an immunogenic component of *L. intracellularis* and includes recombinant molecules, whole cells and cell extracts.

20

In accordance with this aspect of the present invention, the immunogenic components are particularly useful in screening for antibodies to *L. intracellularis* and, hence, provide a diagnostic protocol for detecting *L. intracellularis* infection. Alternatively, biological samples can be directly screened for *L. intracellularis* using antibodies raised to immunogenic  
25 components.

Accordingly, there is provided a method for the diagnosis of *L. intracellularis* infection in a pig comprising contacting a biological sample from said pig with an immunogenic component binding effective amount of an antibody for a time and under conditions sufficient for an  
30 immunogenic component-antibody complex to form, and then detecting said complex.

- 15 -

The presence of immunogenic components (or antibodies thereto) in a pig's blood, serum, or other bodily fluid, can be detected using a wide range of immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. This includes both single-site and two-site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays. Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention.

- 10 Briefly, in a typical forward assay, an immunogenic component-specific antibody is immobilised onto a solid substrate to form a first complex and the sample to be tested for immunogenic component brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-immunogenic component secondary complex, a second immunogenic component antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing sufficient time for the formation of a tertiary complex. Any unreacted material is washed away, and the presence of bound labelled antibody is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparing with a control sample.
- 15 20 The present invention contemplates a range of variations to the subject assay including an assay for *L. intracellularis* antibodies using, for example, recombinant peptides, polypeptides or proteins from this organism.

The solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing the molecule to the insoluble carrier.

By "reporter molecule", as used in the present specification, is meant a molecule which, by its chemical nature, produces an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecule in this type of assay are either enzymes, fluorophores or  
5 radionuclide containing molecules (i.e. radioisotopes). In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognised, however, a wide variety of different conjugation techniques exist which are readily available to one skilled in the art. Commonly used enzymes include horseradish peroxidase, glucose oxidase,  $\beta$ -galactosidase and alkaline phosphatase,  
10 amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. It is also possible to employ fluorogenic substrates, which yield a fluorescent product.

Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be chemically  
15 coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off  
20 the unbound reagent, the remaining ternary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed. It will  
25 be readily apparent to the skilled technician how to vary the procedure to suit the required purpose.

A range of genetic diagnostic assays may be employed such as polymerase chain reaction (PCR) assays, hybridisation assays or protein truncation assays. All such assays are  
30 contemplated in the present invention.

- 17 -

The present invention is further described by the following non-limiting Figures and/or Examples.

In the Figures:

5

Figure 1 is a photographic representation showing Western analysis of *L. intracellularis* antigens recognised by vaccinated pigs. Track 1 (395) was probed with pig sera from a pig (395) that had been immunised three times with the formalin killed whole *L. intracellularis* vaccine. Track 2 to 5 (Y10, Y12, Y14, Y16) were probed with sera obtained from pigs Y10, Y12, Y14 and Y16, respectively on day 0.

Figure 2 is a photographic representation of the small intestine obtained from pig Y1 on day 20.

15 Figure 3 is a photographic representation of the small intestine obtained from pig Y2 on day 20.

Figure 4 is a photographic representation of the small intestine obtained from pig Y4 on day 20.

20

The following single and three letter abbreviations are used for amino acid residues:

5 Amino Acid	Three-letter Abbreviation	One-letter Symbol
Alanine	Ala	A
Arginine	Arg	R
10 Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
15 Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
20 Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
25 Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V
Any residue	Xaa	X

## SUMMARY OF THE SEQUENCE IDENTITY NUMBERS

	SEQ ID NO.	Description
5	1	Nucleotide sequence of GroEL
	2	Amino acid sequence of GroEL
	3	Nucleotide sequence of GroES
	4	Amino acid sequence of GroES
	5	Nucleotide sequence of <i>L. intracellularis</i> component
10	6	Nucleotide sequence of <i>L. intracellularis</i> component
	7	Amino acid sequence of SEQ ID NO:6
	8	Nucleotide sequence of <i>L. intracellularis</i> component
	9	Amino acid sequence of SEQ ID NO:8 (first coding sequence)
	10	Amino acid sequence of SEQ ID NO:8 (second coding sequence)
15	11	Nucleotide sequence of <i>L. intracellularis</i> component
	12	Amino acid sequence of SEQ ID NO:11
	13	Nucleotide sequence of <i>L. intracellularis</i> component
	14	Amino acid sequence of SEQ ID NO:13
	15	Nucleotide sequence of <i>L. intracellularis</i> component
20	16	Amino acid sequence of SEQ ID NO:15
	17	Nucleotide sequence of <i>L. intracellularis</i> component
	18	Nucleotide sequence of <i>L. intracellularis</i> component
	19	Nucleotide sequence of <i>L. intracellularis</i> component
	20	Nucleotide sequence of <i>L. intracellularis</i> component
25	21	Nucleotide sequence of <i>L. intracellularis</i> component
	22	Nucleotide sequence of <i>L. intracellularis</i> component
	23	Nucleotide sequence of <i>L. intracellularis</i> component

- 20 -

# EXAMPLE 1

## SOURCES OF PIG TISSUE

### Infected Pig Intestines

- 5 Sections of grossly thickened ilea were taken from pigs naturally or experimentally affected by PPE. The presence of *L. intracellularis* bacteria in the ilea was confirmed using immunofluorescent staining with specific monoclonal antibodies (10). An example of a suitable antibody is monoclonal antibody IG4 available from the University of Edinburgh, UK.

10

### EXAMPLE 2

## ISOLATION OF *LAWSONIA INTRACELLULARIS* BACTERIA FROM THE INFECTED PIG ILEUM

- Lawsonia intracellularis* bacteria were extracted directly from lesions of PPE in pigs by  
15 filtration and further purified over a Percoll (Pharmacia, Uppsala, Sweden) gradient. Infected ilea were collected from pigs and the presence of *L. intracellularis* was confirmed histologically before storage at -80°C. Sections of ileum were thawed and approximately 8g of infected mucosa were scraped from the intestinal wall. The mucosa was homogenised with 40 ml sterile phosphate buffered saline (PBS) on half speed for 10 s using a Sorvall omnimixer. This  
20 suspension was centrifuged at 2000 xg for 4 minutes. The supernatant was discarded and the cell pellet was resuspended in 40 ml PBS and recentrifuged. This washing step was repeated twice. The cell pellet was then resuspended in 20 ml PBS and homogenised at full speed for one minute to release *L. intracellularis* bacteria.
- 25 This homogenate was centrifuged at 1000 xg for 4 minutes giving a pellet containing a crude mixture of homogenised epithelial cells and intestinal bacteria. The supernatant was filtered using filters with pore sized 3 µm, 1.2 µm and 0.8 µm (Millipore Corporation, MA, USA). The filtrate was centrifuged at 8000 xg for 30 minutes, resulting in a small pellet of *L. intracellularis* bacteria. The *L. intracellularis* bacteria were further purified using a 45% self forming percoll  
30 gradient as follows: 2 mls of the bacterial preparation was mixed by inversion into 30 mls of



- 21 -

a 45% self forming Percoll (Pharmacia LKB, Uppsala, Sweden) gradient (45% v/v of Percoll, 150 mM NaCl). The gradients were centrifuged in a Sorval centrifuge using the SS34 rotor, at 20,000rpm for 30 minutes at 4°C. Usually a number of bands form within the gradient. The band (usually located approx. 10-20mm from the base of the tube) containing the *L. intracellularis* bacteria was collected and the volume made up to 16 mls with PBS. The solution was then centrifuged for 15 minutes at 8000rpm. The resultant pellet was washed with PBS before being resuspended in a final volume of approximately one ml.

### EXAMPLE 3

#### 10 PURIFICATION OF *LAWSONIA INTRACELLULARIS* GENOMIC DNA

Genomic DNA was extracted from percoll-gradient purified *Lawsonia intracellularis* bacteria, recovered from infected pig ilea scrapings (Example 2), by the methods described by Anderson *et al* (11) & Sambrook *et al* (12).

### 15 EXAMPLE 4

#### IMMUNOSCREENING OF GENOMIC LIBRARIES

A lambda ZAP II *L. intracellularis* genomic library was plated on a lawn of *Escherichia coli* XLI-Blue (23) cells at a density of 2,000 plaque-forming units (pfu) per 150 mm L-broth agar plate. The library was screened with a rabbit anti- *L. intracellularis* sera using the method described in the Protoblot Technical Manual (Promega, WI, USA). Filters were blocked in a buffer containing 10mM Tris HCl, pH8.0, 150mM NaCl, 0.05% Tween 20, 1% w/w gelatin. Positive plaques identified in a primary screen were picked, replated at a lower density and rescreened until individual positive plaques were identified.

### 25 EXAMPLE 5

#### ISOLATION AND SEQUENCING OF cDNA INSERTS

Phagemid DNA from positive λZAP II phage clones was isolated by excision *in vivo* of the 30 pBluescript phagemid under the conditions recommended by Stratagene (CA, USA). Plasmid

- 22 -

DNA was either extracted by the method of Birnboim and Doly and the cDNA inserts sequenced by the chain termination method (21), or by the PEG-precipitation method and cycle-sequenced by the dye-terminator method, as recommended by the manufacturer (Applied Biosystems).

5

#### EXAMPLE 6

##### ANTISERA

Antisera to *L. intracellularis* bacteria were raised in rabbits and pigs. Rabbits were injected intramuscularly with a preparation of Percoll gradient-purified *L. intracellularis* bacteria mixed with a double-emulsion made by processing with oil adjuvant (Freund's incomplete adjuvant, CSL Limited, Melbourne, Australia), and then with Tween-80-enhancer. Two 3 ml injections, containing 9 mg protein, were given four weeks apart. Blood samples were collected from the marginal ear vein prior to immunisation and two weeks following the second injection.

15

A 6-week old pig (395) was hyperimmunised by intramuscular injection of Percoll gradient purified *L. intracellularis* bacteria prepared with Freund's incomplete adjuvant as for the rabbit. Three injections of the prepared antigen were administered four weeks apart, and blood was collected from the jugular vein two weeks following the final injection. Diluted pig sera (1 ml, 1 in 200) were pre-absorbed with 100  $\mu$ l *E. coli* DH5 $\alpha$  (24) lysate for 1 h at room temperature with gentle mixing. The lysate was prepared by freeze-thawing a suspension of *E. coli* in PBS.

#### EXAMPLE 7

##### SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)

25

Protein samples were resuspended in 50  $\mu$ l of sample buffer (62.4 mM HCl, 2% w/v SDS, 10% v/v glycerol, 5% v/v 20 mercaptoethanol, 0.002% bromophenol blue, pH 6.8) and heated to 95°C for 5 minutes before separating solubilised proteins electrophoretically on a 0.1% w/v SDS-12% w/v PAGE vertical slab gel (13).

30

- 23 -

### EXAMPLE 8

#### WESTERN BLOTTING

Proteins were electrophoretically transferred to Immobilon-P (Millipore Corporation, MA, USA) membranes in a Trans-Blot Cell (BioRad, CA, USA) at 100 V for 1 h in a buffer containing CAPS (3-[Cyclohexylamino]-l-propanesulfonic acid, pH 11, Sigma, MI, USA) and 10% v/v methanol. The membranes were then blocked with 5% w/v Blotto (Diploma skim milk powder, Melbourne, Australia) in PBS for 30 min at room temperature with gentle rocking. The filters were then transferred to antisera diluted in 5% w/v Blotto, PBS. Pre-absorbed pig antisera was diluted 1 in 200. The filters were incubated in pig antisera for 1 h followed by washing three times in PBST.

HRP conjugated anti-swine immunoglobulins (DAKO, CA, USA) were applied at a dilution of 1:2000. Enhanced Chemiluminescence (ECL, Amersham, IL, USA) was used to discriminate *L. intracellularis* proteins. Prior to ECL detection, blots were washed three times for 7 minutes each. The filters were exposed to autoradiographic film (Agfa, NJ, USA) for less than 1 minute before developing.

### EXAMPLE 9

#### IDENTIFICATION OF GroEL AND GroES

Clones found to be positive according to the immunoscreening method described in Example 4 were sequenced using the protocol detailed in Example 5. One clone isolated represented the GroEL protein. The nucleotide sequence and corresponding amino acid sequence of GroEL are shown in SEQ ID NO:1 and SEQ ID NO:2. Another clone isolated represented the GroES protein. The nucleotide sequence of GroES and corresponding amino acid sequence are shown in SEQ ID NO:3 and SEQ ID NO:4.

- 24 -

**EXAMPLE 10****IMMUNOFLORESCENT DETECTION OF *LAWSONIA INTRACELLULARIS*  
BACTERIA IN PIG FAECES**

5 Faecal swabs of pigs were taken using a cotton tipped swab and then the sample was smeared onto a glass slide. After allowing ten minutes for air drying the smears were heat fixed by heating to 60°C for approximately 10 seconds. The slides were then rinsed in PBS. An amount of 30µl of a 1/200 dilution of a mouse ascites containing IG4 monoclonal antibody (see Example 1) was added, a glass cover slip applied, and the slides were incubated at room  
10 temperature for 40 minutes. The cover slip was removed and the slides were washed (PBST for 7 minutes, three times). An amount of 30µl of a 1/40 dilution of a FITC conjugated anti-mouse antiserum (Silenus, Melbourne Australia) was added, a glass cover slip applied and the slides were incubated at room temperature for 40 minutes. The cover slip was removed and the slides were washed (PBST for 7 minutes X3). The slides were given a final rinse in PBS. A drop of  
15 10% v/v glycerol PBS was added and a glass cover slip applied. The fluorescent bacteria were visualised under highpower (X1200) at 340 nm using a Lietz laborlux S microscope. Twenty fields were counted and the results (see Table 1) were expressed as the average number of *L. intracellularis* bacteria per high powered field.

20

**EXAMPLE 11****FORMALIN-KILLED *L. INTRACELLULARIS* VACCINE**

The percoll gradient purified bacterial *L. intracellularis* pellet was resuspended in 1 ml of 1% formalin in saline and incubated overnight at 4°C. The percoll gradient-purified *L.*  
25 *intracellularis* bacteria was then mixed into a double-emulsion made by processing with oil adjuvant (Freund's incomplete adjuvant, Commonwealth Serum Laboratories, Melbourne, Australia), and then with Tween 80 enhancer.

- 25 -

**EXAMPLE 12****VACCINATION PROTOCOL**

- 5 Twelve weaned pigs (Landrace crossed with Large White) were sourced from a Pig Improvement Company piggery and treated with Neo- Terramycin (0.25 g/kilo) for 5 days. Seven days later (day -40) pigs Y10, Y12, Y14 and Y16 were vaccinated as described. Pigs Y3, Y11 and Y13 were treated for abscess with long acting terramycin on day -34.
- 10 The twelve pigs were divided into three groups and treated as follows:

*Group 1 Infected Controls*

Four pigs (Ear Tag No Y1-Y4) were housed with vaccinated pigs.

15 *Group 2 Whole Bacteria Vaccine*

Four pigs (Ear Tag No. Y10, Y12, Y14 and Y16) were immunised with 0.5 ml formalin killed *L. intracellularis* bacteria emulsified in 0.5 ml of PBS/Freunds incomplete adjuvant on days -33 and -12.

20 *Group 3 Uninfected Controls*

Four pigs (Ear Tag No. Y9, Y11, Y13 and Y15) received no treatments and were housed in a separate area from the vaccinated pigs and infected control pigs.

**EXAMPLE 13**

25

**ORAL CHALLENGES OF INFECTED PIGS**

Infected ilea were collected from pigs as described in Example 1 and the presence of *L. intracellularis* was confirmed histologically before storage at -80°C. Sections of ileum were thawed and approximately 150g of infected mucosa was scraped from the intestinal wall. The  
30 mucosa was homogenised with an equal volume of sterile PBS on half speed for 20 s using a

- 26 -

Sorvall ominimixer. This suspension was diluted two fold with sterile PBS to form the challenge suspension.

On day 0 each pig from Groups 1 and 2 was dosed with a 5% w/v with Na Bicarbonate solution (10 ml/kg) followed by 30 ml of the challenge suspension. This was repeated on day 1 and day 2.

From day 11 onwards, the number of *L. intracellularis* bacteria in each pig's faeces was monitored by immunofluorescence. Pigs were monitored for signs of disease and shedding of *L. intracellularis* bacteria. Pigs shedding greater than 100 bacteria per high powered field and scouring were killed for ethical reasons.

On day 22 the surviving pigs were humanely killed and the small intestines were recovered. Two sections of small intestine were removed 5 cms and 17 cms proximally from the ileocaecal junction. These sections were fixed in 10% v/v formalin, wax embedded and sections were sent to an independent veterinary pathologist for analysis.

#### EXAMPLE 14

##### LAWSONIA INTRACELLULARIS PROTEINS RECOGNISED BY VACCINATED PIGS

20

Antibodies raised by pigs to *L. intracellularis* proteins post vaccination were analysed by Western blotting followed by ECL (Amersham, IL, USA) detection as described in Example 8. The results are shown in Figure 1. Vaccinated pigs produce antibodies to a range of *L. intracellularis* proteins. The most immunodominant proteins recognised are approximately 62.7 Kda, 58.7 Kda, 57.2 Kda, 44 Kda, 36.7 Kda and two smears from 24-26 Kda and 22-23.5 Kda. Minor immunoreactive bands had approximately the following molecular weights 67 Kda, 52.5 Kda, 50.5 Kda, 50 Kda, 48.2 Kda, 47.9 Kda, 44.7 Kda, 43.5 Kda, 42.5 Kda, 41.5 Kda, 40.5 Kda, 39 Kda, 35.3 Kda, 17 Kda, 15.5 Kda, 12 Kda and 7 Kda. The molecular weight of the proteins recognised will vary by up to 5% depending on the method used for estimation.

30

- 27 -

**EXAMPLE 15****SHEDDING OF *L. INTRACELLULARIS* BACTERIA BY PIGS DURING TRIAL**

Three of the pigs from Group 1 (Infected control) in Example No. 12 (Y1, Y2 and Y4) shed  
5 greater than 100 *L. intracellularis* bacteria per high powered field in their faeces by day 19 post  
oral challenge (Table 1). Two of these pig (Y2 and Y4) had a bloody scour. All three pigs were  
humanely killed on day 20. Y3 shed low levels of *L. intracellularis* bacteria during the course  
of the infection trial. Maximal bacterial shedding for Y3 was 16 bacteria per high powered  
field.

10

All pigs in group 3 vaccinated with whole bacteria as set out in Example 12, never shed more  
than 3 *L. intracellularis* bacteria per high powered field. Vaccination with the formalin-killed  
*L. intracellularis* vaccine reduced total bacterial shedding of *L. intracellularis* bacteria by  
vaccinated pigs by 98.5% when compared with group 1 pigs.

15

None of the group 3 pigs (uninfected controls) shed any *L. intracellularis* bacteria during the  
course of the trial.

The results of shedding of *L. intracellularis* bacteria per pig are shown in Table 1.

20

**EXAMPLE 16****GROSS PATHOLOGY FOR TRIAL A***Group 1      Infected Controls*

- 25 Y1      Approximately 5 cm of terminal ileum was grossly thickened. No other signs of PPE  
were evident macroscopically. Findings are consist with intestinal adenomatosis (See  
Figure 2).
- Y2      The intestine was found to be grossly thickened and the serosa had the characteristic  
cerebriform forms (Figure 3). Over 2.5 metres of the intestine was involved. The lumen  
30 of the intestine was found to contain fresh blood and fibrinous casts were evident.

- 28 -

Proliferative haemorrhagic enteropathy.

- Y3 No gross signs of PPE were evident.
- Y4 The intestine was found to have necrotic enteritis (Figure 4). The mucosal surface was replaced with a fibrinous pseudomembrane. Oedema of the mesentery was clearly evident. Over 2.0 meters of intestine was involved.

*Group 2 Whole L. intracellularis cell vaccine*

- Y10 No gross signs of PPE.
- Y12 No gross signs of PPE.
- 10 Y14 No gross signs of PPE.
- Y16 No gross signs of PPE.

*Group 3 Uninfected controls*

- Y9 No gross signs of PPE.
- 15 Y11 No gross signs of PPE.
- Y13 No gross signs of PPE.
- Y15 No gross signs of PPE.

**EXAMPLE 17**

**HISTOPATHOLOGY REPORT FOR TRIAL**

Reports are based on established histopathological descriptions in Jubb *et al* (20).

*Group 1 Infected control group*

- 25 Y1 Numerous microfocal/confluent lesions of Porcine Intestinal Adenomatosis (PIA) are associated with Peyer's Patches.
- Y2 Serious generalised (annular) lesions of Porcine Intestinal Adenomatosis.
- Y3 No conclusive evidence of PIA. Sparse microfocal lesions suggestive of a non-specific mild reactive (reparational) hyperplasia (rather than an adenomatosis).
- 30 Y4 Severe generalised (annular) lesions of PIA.



- 29 -

*Group 2      Whole L. intracellularis cell vaccine*

- Y10   No conclusive evidence of PIA.  
Y12   No conclusive evidence of PIA.  
5 Y14   No conclusive evidence of PIA.  
Y16   No conclusive evidence of PIA. Possible single microfocus of PIA is associated with  
Peyers Patch.

*Group 3      Uninfected controls*

- 10 Y11   No conclusive evidence of PIA.  
Y9   No conclusive evidence of PIA.  
Y13   Intestine was not recovered since pig was killed due to lameness at day 15.  
Y15   Diagnosis not possible because of the poor quality sections.

15

**EXAMPLE 18****IMMUNOSCREENING OF A *L. INTRACELLULARIS* LIBRARY USING  
EXPERIMENTAL SERA FROM VACCINATED PIGS**

- 20 *L. intracellularis* genomic DNA was purified as described in Example 3. The DNA was partially digested with the restriction endonuclease *Sau3A* (Promega) and ligated into Lambda ZAP II Express (Stratagene). The lambda library was plated on a lawn of *E. coli* XLI-Blue cells at a density of 10,000 pfu per 150 Mm L-broth agar plate. The library was screened, as described in Example 4, with sera from Y12. The pig Y12 was immunised with formalin killed  
25 *L. intracellularis*, as described in Example 11 & 12. Vaccinated pigs produced antibodies to a range of *L. intracellularis* proteins, as described in Example 14. A number of phage clones expressing *L. intracellularis* proteins were identified.

**EXAMPLE 19****ANALYSIS OF *L. INTRACELLULARIS* EXPRESSING PHAGE CLONES**

5 Phagemid DNA from positive λZAP II Express phage clones was isolated by *in vivo* excision, by the conditions recommended by the manufacturer (Stratagene). Plasmid DNA, for restriction analysis was extracted by alkaline-lysis, as described by Sambrook *et al* (12), and for automated sequencing, using the High Pure Plasmid Kit, as recommended by the manufacturer (Boehringer Mannheim). DNA sequencing of inserts was performed by the Dye-  
10 terminator method of automated sequencing (ABI Biosystems). The sequences identified are set out in SEQ ID NOS: 5-23 (see Example 20).

**EXAMPLE 20****IDENTIFICATION OF *L. INTRACELLULARIS* COMPONENTS**

15

Sequence similarity of the DNA molecules encoding putative vaccine candidates identified from Example 18 and 19, was identified using BLAST (27). Nucleotide sequence SEQ ID NO:6 and its corresponding amino acid sequence SEQ ID NO:7 have sequence similarity to flagellar basal body rod protein. SEQ ID NO:8 (nucleotide) and SEQ ID NOS:9 and 10  
20 (amino acid) have sequence similarity to autolysin. SEQ ID NO:11 (nucleotide) and SEQ ID NO:12 (amino acid) show sequence similarity to S-adenosylmethionine: tRNA ribosyltransferase-isomerase (queuosine biosynthesis protein queA).



SEQ ID NO:13 (nucleotide) and SEQ ID NO:14 (amino acid) show sequence similarity to  
25 enoyl-(acyl-carrier-protein) reductase. SEQ ID NO:15 (nucleotide) and SEQ ID NO:16 (amino acid) show sequence similarity to a glucarate transporter. Other nucleotide sequences encoding putative vaccine candidates are SEQ ID NO:5, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23.

30 Those skilled in the art will appreciate that the invention described herein is susceptible to

- 31 -

variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more  
5 of said steps or features.

TABLE 1



- 32A -

TABLE 1

Vaccination										Challenge									
Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	Day	
-40	-33	-26	-12	0	1	2	11	12	13	14	15	16	17	18	19	20	21	22	
1 infected controls						1 +	1 +	0	0	5 +	10 +	50 +	100 +	15	5 cm of thickening				
2 infected controls						0	1 +	1 +	1 +	3 +	1 +	70 +	100 +	100	PHE 2.5 M				
3 infected controls						0	0	0	0	0	0	1 +	4	16	1 +	0	1		
4 infected controls						1 +	0	0	10 +	0	5 +	60 +	200 +	80	PHE 2.0 M				
10 whole bugs							0	0	0	0	0	1 +	1 +	0	0	0	0	0	
1 ml killed whole cell 1 ml killed whole cell																			

SUBSTITUTE SHEET (RULE 26)

[illegible]

## BIBLIOGRAPHY

- 1 Barker, I.K. and Van Dreumel, A.A. (1985) In "Pathology of Domestic Animals," 3rd Edition, Vol. 2 p. 1-237, eds K.V.F. Jubb, P.C. Kennedy and N. Palmer. (Academic Press: Orlando).
- 2 Rowland, A.C. and Lawson, G.H.K. (1976) *Veterinary Record* 97:178-180.
- 3 Love, R.J. and Love, D.M. (1977) *Veterinary Record* 100:473
- 4 Jonsson, L. and Martinsson, K. (1976) *Acta Veterinaria Scandinavica* 17:223-232.
- 5 O'Neil, I. P.A. (1970) *Veterinary Record* 87:742-747.
- 6 Straw, B.E. (1990). *Journal of American Veterinary Medical Association* 197: 355-357.
- 7 Stills, H.F. (1991). *Infection and immunology* 59: 3227-3236.
- 8 Gebbert, C.J., Ward, G.E., Chang, K. And Kurtz, H.J. (1983). *American Journal of Veterinary Research* 44:361-367.
- 9 Lawson, G.H.K., McOrist, S., Jansi, S. and Mackie, R.A. (1993) *Journal of Clinical Microbiology* 31:1136-1142.
- 10 McOrist, S., Boid, R., Lawson, G.H.K. and McConnell, I. (1987) *The Veterinary Record* 121:421-422.
- 11 Anderson, B.J., M.M. Bills, J.R. Egerton, and J.S. Mattick. (1984) *Journal of Bacteriology* 160:748-754.

12. Sambrook, J., E.F. Fritsch, and T. Maniatis. (1989) *Molecular cloning. A laboratory manual. Second edition. Cold Spring Harbour Laboratory, Cold Spring Harbour, N.Y.*
13. Laemmli, U.K. (1970) *Nature* 227: 680-685.
14. McOrist, S, Jasni, S, Mackie, RA, MacIntyre, N, Neef, N. and Lawson GHK (1993) *Infection and Immunity* 61: 4286-4292.
15. Fox, JG, Murphy, JC, Otto, G Pecquet-Goad, ME, Larson, QHK and Scott JA (1989) *Veterinary Pathology* 26: 515-517.
16. Elwell, MR, Chapman, AL and Frenkel, JK (1981) *Veterinary Pathology* 18: 136-139.
17. Schodeb, TR and Fox JG (1990) *Veterinary Pathology* 27: 73-80.
18. Mason, RW, Monkton, P and Hasse D (1995) *Australian Veterinary Journal* (in press).
19. Manthorpe, M, Cornefert-Jensen, F., Hartikka, J., Felgner, J, Rundell, A, Margalith, M and Dwarki, V. (1993) *Human Gene Therapy* 4: 419-431.
20. Jubb KVC, Kennedy, PC and Palmer, NC (1993). *The Pathology of Domestic Animals* 4th ed. San Diego, CA, Academic Press pp 229-233.
21. Birnboim, HC and Doly J (1979) *Nucleic Acids Research* 7: 1513.
22. Sanger, F, Nicklen, S and Coulson, AR (1977) *Proceedings of the National Academy of Science* 74: 5463.



23. Block, WO, Fernandes, JM and Short, JM (1987) *Biotechnics* 5: 376-79.
24. Woodcock, DM *et al* (1989) *Nucleic Acids Research* 17: 3469-78.
25. Studier, FW *et al* (1990) *Methods in Enzymology* 185: 60-89.
26. McOrist, S *et al* (1995) *International Journal of Systematic Bacteriology* 45: 820-825.
27. Gish, W and States, D.J. (1993) *Nature Genetics* 3: 266-272.

- 36 -

SEQUENCE LISTING

(I) GENERAL INFORMATION:

(i) APPLICANT: (OTHER THAN US) DARATECH PTY LTD and PIG RESEARCH.  
(US ONLY): MICHAEL PANACCIO and DETLEF HASSE

(ii) TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC  
COMPOSITIONS

(iii) NUMBER OF SEQUENCES: 23

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: DAVIES COLLISON CAVE

(B) STREET: 1 LITTLE COLLINS STREET

(C) CITY: MELBOURNE

(D) STATE: VICTORIA

(E) COUNTRY: AUSTRALIA

(F) ZIP: 3000

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) PCT INTERNATIONAL

(B) FILING DATE: 29-NOV-1996

(vii) PRIOR APPLICATION DATA:

- 37 -

(A) APPLICATION NUMBER: PN6911/95

(B) FILING DATE: 30-NOV-1995

(A) APPLICATION NUMBER: PN6910/95

(B) FILING DATE: 30-NOV-1995

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: HUGHES DR, E JOHN L

(C) REFERENCE/DOCKET NUMBER: EJH/AF

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9254 2777

(B) TELEFAX: +61 3 9254 2770

- 38 -

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1647 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1647

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GCT TCT AAA GAA ATC CTT TTT GAT GCT AAA GCC CGT GAA AAA CTT	48
Met Ala Ser Lys Glu Ile Leu Phe Asp Ala Lys Ala Arg Glu Lys Leu	
1 5 10 15	
TCA CGA GGT GTA GAT AAA CTT GCA AAT GCT GTT AAA GTA ACA CTT GGA	96
Ser Arg Gly Val Asp Lys Leu Ala Asn Ala Val Lys Val Thr Leu Gly	
20 25 30	
CCT AAA GGC CGT AAT GTC GTT ATT GAA AAG TCT TTT GGT TCC CCA GTT	144
Pro Lys Gly Arg Asn Val Val Ile Glu Lys Ser Phe Gly Ser Pro Val	
35 40 45	
ATT ACA AAA GAT GGT GTA TCT GTT GCA AAA GAA ATT GAA CTT GAA GAT	192
Ile Thr Lys Asp Gly Val Ser Val Ala Lys Glu Ile Glu Leu Glu Asp	
50 55 60	
AAG TTT GAA AAT ATG GGC GCT CAA ATG GTT AAA GAA GTA GCT CCC AAA	240
Lys Phe Glu Asn Met Gly Ala Gln Met Val Lys Glu Val Ala Pro Lys	
65 70 75 80	

- 39 -

ACT AGC GAT ATT GCT GGT GAT GGA ACT ACA ACA GCA ACA GTC CTT GCA	288
Thr Ser Asp Ile Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala	
85 90 95	
CAA GCT ATT TAT CGT GAA GGT GTA AAA CTT GTA GCA GCT GGT CGT AAT	336
Gln Ala Ile Tyr Arg Glu Gly Val Lys Leu Val Ala Ala Gly Arg Asn	
100 105 110	
CCT ATG GCC ATT AAA CGT GGC ATA GAT AAA GCT GTT GTT GCT GTT ACT	384
Pro Met Ala Ile Lys Arg Gly Ile Asp Lys Ala Val Val Ala Val Thr	
115 120 125	
AAA GAA CTA AGC GAC ATT ACA AAG CCT ACT CGT GAC CAA AAA GAA ATA	432
Lys Glu Leu Ser Asp Ile Thr Lys Pro Thr Arg Asp Gln Lys Glu Ile	
130 135 140	
GCT CAA GTT GGA ACC ATT TCT GCA AAC TCT GAT ACA ACA ATA GGT AAT	480
Ala Gln Val Gly Thr Ile Ser Ala Asn Ser Asp Thr Thr Ile Gly Asn	
145 150 155 160	
ATC ATA GCT GAA GCT ATG GCT AAA GTT GGA AAA GGA GGT GTT ATC ACA	528
Ile Ile Ala Glu Ala Met Ala Lys Val Gly Lys Gly Gly Val Ile Thr	
165 170 175	
GTT GAG GAA GCT AAA GGT CTT GAA ACT ACA TTA GAT GTG GTT GAA GGA	576
Val Glu Glu Ala Lys Gly Leu Glu Thr Thr Leu Asp Val Val Glu Gly	
180 185 190	
ATG AAG TTT GAC CGT GGC TAC CTC TCT CCA TAC TTT GTA ACT AAT CCT	624
Met Lys Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Val Thr Asn Pro	
195 200 205	
GAG AAA ATG GTT TGT GAA CTT GAT AAC CCT TAT ATC CTT TGT AAT GAG	672
Glu Lys Met Val Cys Glu Leu Asp Asn Pro Tyr Ile Leu Cys Asn Glu	
210 215 220	
AAA AAG ATT ACT AGC ATG AAA GAC ATG CTA CCA ATC TTA GAA CAA GTT	720



- 41 -

370	375	380	
ACT GAA ACT GAA ATG AAA GAG AAG AAG GAT CGT GTA GAA GAT GCT CTA			1200
Thr Glu Thr Glu Met Lys Glu Lys Lys Asp Arg Val Glu Asp Ala Leu			
385	390	395	400
AAT GCA ACA AGA GCT GCG GTT GAA GAA GGT ATT GTC CCT GGT GGT GGT			1248
Asn Ala Thr Arg Ala Ala Val Glu Glu Gly Ile Val Pro Gly Gly Gly			
405	410	415	
ACT GCT TTT GTC CGC TCC ATT AAA GTC CTT GAT GAT ATT AAA CCT GCT			1296
Thr Ala Phe Val Arg Ser Ile Lys Val Leu Asp Asp Ile Lys Pro Ala			
420	425	430	
GAT GAT GAT GAA CTT GCT GGA CTT AAT ATC ATC CGT CGT TCT CTT GAA			1344
Asp Asp Asp Glu Leu Ala Gly Leu Asn Ile Ile Arg Arg Ser Leu Glu			
435	440	445	
GAG CCT TTA CGT CAA ATT GCT GCA AAT GCT GGC TAT GAA GGT TCT ATT			1392
Glu Pro Leu Arg Gln Ile Ala Ala Asn Ala Gly Tyr Glu Gly Ser Ile			
450	455	460	
GTT GTA GAA AAA GTT CGT GAA CCA AAA GAT GGT TTT GGA TTT AAT GCT			1440
Val Val Glu Lys Val Arg Glu Pro Lys Asp Gly Phe Gly Phe Asn Ala			
465	470	475	480
GCA TCA GGA GAA TAT GAA GAC CTT ATT AAA GCT GGT GTC ATT GAT CCT			1488
Ala Ser Gly Glu Tyr Glu Asp Leu Ile Lys Ala Gly Val Ile Asp Pro			
485	490	495	
AAA AAA GTT ACA CGT ATT GCA TTA CAA AAT GCA GCA TCA GTA GCC TCC			1536
Lys Lys Val Thr Arg Ile Ala Leu Gln Asn Ala Ala Ser Val Ala Ser			
500	505	510	
TTA CTT CTA ACT ACA GAA TGC GCT ATT GCT GAA AAA CCA GAA CCT AAA			1584
Leu Leu Leu Thr Thr Glu Cys Ala Ile Ala Glu Lys Pro Glu Pro Lys			
515	520	525	

- 42 -

AAA GAT ATG CCT ATG CCT GGC GGT GGT ATG GGT GGT ATG GGT GGT ATG 1632  
 Lys Asp Met Pro Met Pro Gly Gly Gly Met Gly Gly Met Gly Gly Met  
 530 535 540

GAC GGT ATG TAC TAG 1647  
 Asp Gly Met Tyr  
 545

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 548 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Ser Lys Glu Ile Leu Phe Asp Ala Lys Ala Arg Glu Lys Leu  
 1 5 10 15  
 Ser Arg Gly Val Asp Lys Leu Ala Asn Ala Val Lys Val Thr Leu Gly  
 20 25 30  
 Pro Lys Gly Arg Asn Val Val Ile Glu Lys Ser Phe Gly Ser Pro Val  
 35 40 45  
 Ile Thr Lys Asp Gly Val Ser Val Ala Lys Glu Ile Glu Leu Glu Asp  
 50 55 60  
 Lys Phe Glu Asn Met Gly Ala Gln Met Val Lys Glu Val Ala Pro Lys  
 65 70 75 80  
 Thr Ser Asp Ile Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala  
 85 90 95



- 43 -

Gln Ala Ile Tyr Arg Glu Gly Val Lys Leu Val Ala Ala Gly Arg Asn  
100 105 110

Pro Met Ala Ile Lys Arg Gly Ile Asp Lys Ala Val Val Ala Val Thr  
115 120 125

Lys Glu Leu Ser Asp Ile Thr Lys Pro Thr Arg Asp Gln Lys Glu Ile  
130 135 140

Ala Gln Val Gly Thr Ile Ser Ala Asn Ser Asp Thr Thr Ile Gly Asn  
145 150 155 160

Ile Ile Ala Glu Ala Met Ala Lys Val Gly Lys Gly Gly Val Ile Thr  
165 170 175

Val Glu Glu Ala Lys Gly Leu Glu Thr Thr Leu Asp Val Val Glu Gly  
180 185 190

Met Lys Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Val Thr Asn Pro  
195 200 205

Glu Lys Met Val Cys Glu Leu Asp Asn Pro Tyr Ile Leu Cys Asn Glu  
210 215 220

Lys Lys Ile Thr Ser Met Lys Asp Met Leu Pro Ile Leu Glu Gln Val  
225 230 235 240

Ala Lys Val Asn Arg Pro Leu Leu Ile Ile Ala Glu Asp Val Glu Gly  
245 250 255

Glu Ala Leu Ala Thr Leu Val Val Asn Lys Leu Arg Gly Ala Leu Gln  
260 265 270

Val Val Ala Val Lys Ala Pro Gly Phe Gly Glu Arg Arg Lys Ala Met  
275 280 285

Leu Glu Asp Ile Ala Ile Leu Thr Gly Gly Glu Ala Ile Phe Glu Asp

- 44 -

290	295	300	
Arg Gly Ile Lys Leu Glu Asn Val Ser Leu Ser Ser Leu Gly Thr Ala			
305	310	315	320
Lys Arg Val Val Ile Asp Lys Glu Asn Thr Thr Ile Val Asp Gly Ala			
325	330	335	
Gly Lys Ser Glu Asp Ile Lys Ala Arg Val Lys Gln Ile Arg Ala Gln			
340	345	350	
Ile Glu Glu Thr Ser Ser Asp Tyr Asp Arg Glu Lys Leu Gln Glu Arg			
355	360	365	
Leu Ala Lys Leu Val Gly Gly Val Ala Val Ile His Val Gly Ala Ala			
370	375	380	
Thr Glu Thr Glu Met Lys Glu Lys Lys Asp Arg Val Glu Asp Ala Leu			
385	390	395	400
Asn Ala Thr Arg Ala Ala Val Glu Glu Gly Ile Val Pro Gly Gly Gly			
405	410	415	
Thr Ala Phe Val Arg Ser Ile Lys Val Leu Asp Asp Ile Lys Pro Ala			
420	425	430	
Asp Asp Asp Glu Leu Ala Gly Leu Asn Ile Ile Arg Arg Ser Leu Glu			
435	440	445	
Glu Pro Leu Arg Gln Ile Ala Ala Asn Ala Gly Tyr Glu Gly Ser Ile			
450	455	460	
Val Val Glu Lys Val Arg Glu Pro Lys Asp Gly Phe Gly Phe Asn Ala			
465	470	475	480
Ala Ser Gly Glu Tyr Glu Asp Leu Ile Lys Ala Gly Val Ile Asp Pro			
485	490	495	

- 45 -

Lys Lys Val Thr Arg Ile Ala Leu Gln Asn Ala Ala Ser Val Ala Ser  
 500 505 510

Leu Leu Leu Thr Thr Glu Cys Ala Ile Ala Glu Lys Pro Glu Pro Lys  
 515 520 525

Lys Asp Met Pro Met Pro Gly Gly Gly Met Gly Gly Met Gly Gly Met  
 530 535 540

Asp Gly Met Tyr  
 545

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 306 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..306

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATG AAC CTG AAA CCT TTG AAT GAC CGT GTT TTA GTA AAA CGT CTT GAA 48  
 Met Asn Leu Lys Pro Leu Asn Asp Arg Val Leu Val Lys Arg Leu Glu  
 1 5 10 15

TCT GAA GAA AAA ACA GCT GGT GGA CTC TAT ATC CCT GAT ACT GCT AAA 96  
 Ser Glu Glu Lys Thr Ala Gly Gly Leu Tyr Ile Pro Asp Thr Ala Lys  
 20 25 30

- 46 -

GAA AAA CCA TCT CGT GGT GAA GTT GTT GCT GTT GGA CCT GGT AAA CAT	144
Glu Lys Pro Ser Arg Gly Glu Val Val Ala Val Gly Pro Gly Lys His	
35 40 45	
ACA GAT GAT GGT AAA TTA ATA CCT ATG GCT GTA AAA GCA GGA GAT ACA	192
Thr Asp Asp Gly Lys Leu Ile Pro Met Ala Val Lys Ala Gly Asp Thr	
50 55 60	
GTT CTT TTT AAT AAG TAT GCA GGA ACA GAA GTA AAG CTT GAT GGT GTA	240
Val Leu Phe Asn Lys Tyr Ala Gly Thr Glu Val Lys Leu Asp Gly Val	
65 70 75 80	
GAG CAT CTA GTT ATG CGT GAA GAT GAC ATC CTA GCT GTT ATT ACT GGA	288
Glu His Leu Val Met Arg Glu Asp Asp Ile Leu Ala Val Ile Thr Gly	
85 90 95	
GAA ACT GGC CGC AAG TGA	306
Glu Thr Gly Arg Lys *	
100	

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 101 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Asn Leu Lys Pro Leu Asn Asp Arg Val Leu Val Lys Arg Leu Glu
1 5 10 15
Ser Glu Glu Lys Thr Ala Gly Gly Leu Tyr Ile Pro Asp Thr Ala Lys

- 47 -

20                      25                      30  
 Glu Lys Pro Ser Arg Gly Glu Val Val Ala Val Gly Pro Gly Lys His  
 35                      40                      45  
 Thr Asp Asp Gly Lys Leu Ile Pro Met Ala Val Lys Ala Gly Asp Thr  
 50                      55                      60  
 Val Leu Phe Asn Lys Tyr Ala Gly Thr Glu Val Lys Leu Asp Gly Val  
 65                      70                      75                      80  
 Glu His Leu Val Met Arg Glu Asp Asp Ile Leu Ala Val Ile Thr Gly  
 85                      90                      95  
 Glu Thr Gly Arg Lys  
 100

## (2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 4972 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AACTCCTGGT CTATCAAGAT CAACTAAAAA ATATTCTTTA TCTAATAGTT	50
GCTCAAAAAT AATTGTACCT ACAGGTAAAT GAAGAATCAA ATCTTCCCCT	100
TTTTACCAT GACGCTGGCT CCCTTTACCA CCTTCTCCAT TTGAGCTCT	150
ATAGTGACGT TGCACACGAA AATCATAAAG GGTTAACAAA CGTGAATCAG	200
CTTTAAAAAT TATATTACCT CCATCTCCTC CATCCCCTCC ATTAGGTCCA	250

CCTTTAGGTA TAACTTTTC GCGTCTAAAT GAAACACATC CATTTCACC	300
TTTTCTGCG CTCACGCTAA TAGTTACTTC ATCAACAAAA CGCATGATTA	350
TCCTTTCAAT AACAAATATC TATTCAATAC TGTTACTAAC TTGTTTACTG	400
TTTTTTCTAG AAAATTACCT GGCTAATTAT TATAGTTATA TCTAGATTAA	450
TGAAAAAGGA AGAAGTCATT ACCTCCTTC CTTATTAATA GAATCCTGGA	500
ATAATTATTA TACGGTGGGT TGTATATGCA CTCTACTATA TCCTTTACAT	550
TTACGAAAAT ATGTTTCATA AGTTACTATA CCATTAACTT TTGCAAATAA	600
AGTATAGTCT CTTCCCATTC CAACATTTTC TCCAGGATGA ATTTTGTAC	650
CTAGTTGACG AACAAAGGATA TTGCCTGCCA AGACTTTCTG GCCGCCGAAA	700
CGCTTTATAC CACGACGTTG TCCTGGACTA TCTCTACCAT TCGGAGAACT	750
TCCACCAGCT TTCTTATGGG CCATTTTAAT ATCTCCTTAA AGCTGAATAC	800
CTGTTACTTT TAGAGCTGTA TAGTCTGAC GATGACCTTG GAGTTTACGT	850
GAGTCATTTT TTCTCCACTT TTAAAAACA AGAATTTTTT TATCACGACC	900
ATGCTCAAGA ACTTTAGCTA TAACTTTAGC ATTATTAATA TATGGTGTTC	950
CAATTTGAGG AGATGAACCA CCAATCATAA AAATTTTATC AAAAAAATT	1000
TCTGTTCCAA CTTGACGCTC TATTTTAGAA AAAAAATTT TAGAACCTTC	1050
TTCAACACAG AATTGTTTTT CACCAGCTTC AATAATTGCG TACATAAATA	1100
ATGTGCCTCC CAAAAAGAC AAGAAATACT AATTGATAT TTTCAATATT	1150
GTCAAGTAGG AACTTTATCT TTAGAATGTT AGATGTAACA ATTTTTTTAG	1200
AAAAAAATA TTTTCAATAC AATAGGAAAA GAGGAAAAAA AAAAAGATTT	1250
TTAGAAAAAA TTTTATTTT TCCAAAAAT GCAAAATAT AAAAAATTCT	1300
AATAGGATAG AAGTTATTAC TGTATTGATT TTCAAGACTT ACTTAAAAAT	1350
TTTTATAAAA AAATTTGCAT TCCCCTCTTC CCAATTCCA TAGAGAAGAT	1400
TATTTATCCT AACGATTGGT GGACGCTAAG TCCCTGCTGT TTTGATTATA	1450
TATCAAATGT TGAAACAAAT TTTGTTTAGT TTCTTTTGT ACTCTAAAAA	1500
GAAGACAAAA AATTCTTTAT AACTGTACA CTCTAAACAA AATAGTTCAC	1550
AATAAACAGC AATACATTAT AATTAATTGG AGGATACTAT TGTCATGAAC	1600
CTGAAACCTT TGAATGACCG TGTTTTAGTA AAACGCTCTG AATCTGAAGA	1650
AAAAACAGCT GGTGGACTCT ATATCCCTGA TACTGCTAAA GAAAAACCAT	1700
CTCGTGGTGA AGTTGTTGCT GTTGACCTG GTAAACATAC AGATGATGGT	1750
AAATTAATAC CTATGGCTGT AAAAGCAGGA GATACAGTTC TTTTAAATAA	1800
GTATGCAGGA ACAGAAGTAA AGCTTGATGS TGTAGAGCAT CTAGTTATGC	1850
GTGAAGATGA CATCCTAGCT GTTATTACTG GAGAACTGG CCGCAAGTGA	1900
AAAAGGCGTA AATAAAAAGA TCGGTGATCT TTAATAATTT TATTCAGTTA	1950
TAATGAAAC ACTAATTACA CGCACTCTCT GAGAATTTTC TCAGAAAACT	2000
ATATTTAACA ATTCTAAAA CGATATGTTT TTAGGAGGAA AACCCTAATG	2050
GCTTCTAAAG AAATCCTTTT TGATGCTAAA GCCCGTGAAA AACTTTCACG	2100

AGGTGTAGAT AAACCTGCAA ATGCTGTTAA AGTAACACTT GGACCTAAAG	2150
GCCGTAATGT CGTTATTGAA AAGTCTTTTG GTTCCCCAGT TATTACAAAA	2200
GATGGTGTAT CTGTTGCAAA AGAAATTGAA CTGAAGATA AGTTTGAAAA	2250
TATGGGCGCT CAAATGGTTA AAGAAGTAGC TCCCAAAACT AGCGATATTG	2300
CTGGTGATGG AACTACAACA GCAACAGTCC TTGCACAAGC TATTTATCGT	2350
GAAGGTGTAA AACTGTAGC AGCTGGTCGT AATCCTATGG CCATTAAACG	2400
TGGCATAGAT AAAGCTGTTG TTGCTGTTAC TAAAGAACTA AGCGACATTA	2450
CAAAGCCTAC TCGTGACCAA AAAGAAATAG CTCAAGTTGG AACCATTCT	2500
GCAAACCTCTG ATACAACAAT AGGTAATATC ATAGCTGAAG CTATGGCTAA	2550
AGTTGGAAAA GGAGGTGTTA TCACAGTTGA GGAAGCTAAA GGTCTTGAAA	2600
CTACATTAGA TGTGGTTGAA GGAATGAAGT TTGACCGTGG CTACCTCTCT	2650
CCATACTTTG TAACTAATCC TGAGAAAATG GTTTGTGAAC TTGATAACCC	2700
TTATATCCTT TGTAAATGAGA AAAAGATTAC TAGCATGAAA GACATGCTAC	2750
CAATCTTAGA ACAAGTTGCT AAAGTAAACC GTCCACTCCT TATTATTGCT	2800
GAAGACGTAG AAGGTGAAGC ACTTGCAACA CTTGTAGTCA ATAAGCTCCG	2850
TGGAGCACTC CAAGTTGTAG CCGTAAAAGC TCCTGGTTTT GGTGAACGCC	2900
GTAAGCTAT GCTTGAAGAT ATTGCTATCC TTACTGGAGG AGAAGCAATA	2950
TTTGAAGATC GTGGTATAAA GCTTGAAAAT GTAAGCTTGT CTCTTTTAGG	3000
AACAGCTAAA CGTGTAGTTA TTGACAAAGA AAATACTACT ATCGTTGATG	3050
GTGCTGGAAA ATCAGAAGAT ATTAAAGCTC GAGTTAAACA AATTCTGCA	3100
CAAATTGAAG AAACAAGCTC AGATTATGAT CGTGAAAAAC TTCAAGAACG	3150
TCITGCAAAA CTGTGTTGGT GAGTAGCTGT TATCCATGTT GGAGCTGCTA	3200
CTGAACTGA AATGAAAGAG AAGAAGGATC GTGTAGAAGA TGCTCTAAAT	3250
GCAACAAGAG CTGCGGTTGA AGAAGGTATT GTCCCTGGTG GTGGTACTGC	3300
TTTTGTCCGC TCCATTAAAG TCCTTGATGA TATTAAACCT GCTGATGATG	3350
ATGAACTTGC TGGACTTAAT ATCATCCGTC GTTCTCTTGA AGAGCCTTTA	3400
CGTCAAATTG CTGCAATGC TGGCTATGAA GGTTCTATTG TTGTAGAAAA	3450
AGTTCGTGAA CCAAAGATG GTTTTGGATT TAATGCTGCA TCAGGAGAAT	3500
ATGAAGACCT TATTAAAGCT GGTGTCATTG ATCCTAAAAA AGTTACACGT	3550
ATTGCATTAC AAAATGCAGC ATCAGTAGCC TCCTTACTTC TAACTACAGA	3600
ATGCGCTATT GCTGAAAAAC CAGAACCTAA AAAAGATATG CCTATGCCTG	3650
GCGGTGGTAT GGGTGGTATG GGTGGTATGG ACGGTATGTA CTAGTCCTAT	3700
CTTCAGTACA ACTTAGATGT ATAAAAACCC CAGAAGCAAT GCTTCCGGGG	3750
TTTTTACTT TCAGCATAAA AAATTAATAT TTAATATACA GACACATTAT	3800
TTTGGTATTT ATTATTTATT ATGATCAAAT ATATAGACTG GATACAAAAA	3850
ACAACAATGA TGTTTAAAAA GGCAGGGATA GATTCAACAA AACTCTCTGC	3900
AGAACTTATA TTAAGTCATG TTTTAAATAT TACACGATTA CAAATAATAA	3950

- 50 -

TGACTCCTTT TGAACCTATT CCAACTAATA GCTACTCAAC GCTTAATGAT	4000
ATCATGTTAA GAAGACTCCA TGGAGAACCA ATTGCATATC TCACAGGGAA	4050
AAAAGAATTT TTTTCACGAG AATTTAAAGT CACTCAAGCC ACACCTTATCC	4100
CTCGCCCAGA GACAGAGTTA CTTATAGAAT TTGTATTAAA CCATATTAAC	4150
CCAACACAAC AAATATACTT TGCAGACTTA GGTACAGGTA GTGGGTGTAT	4200
TGCAATTACA CTAGCTGCTG AAAGAAAAAA TTGGTTAGGT ATTGCTACTG	4250
ATATCTCTAG TGAAGCATTAA AAAATAGCTA AACTTAATAG TTTAAAAAAT	4300
AACACTCATA GTCAACTACA GTTTCCTTCAA TCAGATTTTA CACAACCACT	4350
CTGTCTACCC TCTTCATTAG ACTTATATAT CAGTAATCCT CCATATATAA	4400
GTGAAAATGA ACTGACCTCT CTTCCGCATG AAGTAATATC TTTTGAACCT	4450
AAAATAGCTC TTACACCACA TAAATGTATT CATCTTGATG AAATAAATAC	4500
CGTTTTACAC TGCTATAAAA AAATTATTAC CCAAGCAGAG ATATCCCTTA	4550
AGCCTGCAGG AATAATAATT TTAGAACATG GAGCAACACA AGCAGAAGCT	4600
ATCTTATTGT TGTAAAAAAA CAACATATGG AGAAATGTAA TAAGTCATAC	4650
TGATCTTACA AATAAAAAATC GTTTTATTAC AGEATATAAG TATAAAATAT	4700
AACCTTAATTA TGTTGkagAa AAAACAAAAA ATAAAAATAA GATATtAAaT	4750
ATTTtttttA aTAAaATTAA GCAAtTACTA ATATCTTTTT TTGGrTCGtt	4800
yaTtGgATwA GAAACTTTGG rGGrTrCTa TGAACRAACA ACCATnCAAC	4850
GGCCAAATAC ATnnCAGGnT TGGGGTCATA GGGGCCACGC TTTATGTACG	4900
TACAACCCCh ACTGAAATTC TGGnTTGnTT TGGGGGGnAA nTGGGTATCG	4950
CAACnCTnTC CCCCCCCCCT GG	4972

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 569 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 209..569



- 51 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGTTAAAAAG TAAGCAGAAA AGGTTGGTTA AACCAAGTTT AAAAAATTAA TTTTTTTTTA	60
TTACCCAAAA AAGTTTATTA GATTAAGTAA TATTAATTG GCCCAAAAT TTTTGGGC	120
ATGGGTTTTT TGCTTTTAAA ATAGAGATGT GTAGGTAACA TTTTTCCTC CATGAAATTA	180
TTTTTTAGGA GATGTTATCA TGATGGGG AGT TTG TTT ATT GNT GCG AAC AGG	232
Ser Leu Phe Ile Xaa Ala Asn Arg	
1 5	
TAT GAA AAC CCA TAG NAC AGG GNT GGT ACT GTC TCC AAT AAT ATT GCT	280
Tyr Glu Asn Pro * Xaa Arg Xaa Gly Thr Val Ser Asn Asn Ile Ala	
10 15 20	
AAC GCA AAT ACC ATT GGG TAT AAG CAG CAA CAG GTA GTG TTT CAA GAC	328
Asn Ala Asn Thr Ile Gly Tyr Lys Gln Gln Gln Val Val Phe Gln Asp	
25 30 35 40	
CTG TTT AGT CAA GAT TTA GCA ATA GGT TTT ACT GGA AGT CAG GGG CCA	376
Leu Phe Ser Gln Asp Leu Ala Ile Gly Phe Thr Gly Ser Gln Gly Pro	
45 50 55	
AAC CAG GCT GGT ATG GGA GCA CAG GTG GGA AGT GTT CGC ACA ATT TTT	424
Asn Gln Ala Gly Met Gly Ala Gln Val Gly Ser Val Arg Thr Ile Phe	
60 65 70	
ACA CAG GGT GCT TTT GAA CCT GGC AAT AGT GTA ACA GAT CCT GCT ATT	472
Thr Gln Gly Ala Phe Glu Pro Gly Asn Ser Val Thr Asp Pro Ala Ile	
75 80 85	
GGT GGA AAA GGT TTT TTT CAG GTT ACA TTA GAG GAT AAA GTA CAC TAT	520
Gly Gly Lys Gly Phe Phe Gln Val Thr Leu Glu Asp Lys Val His Tyr	
90 95 100	

- 52 -

ACA CGA GCA GGG AAT TTT CGT TTT ACT CAA GAT GGT TTT TTA AAT GAT C 569  
 Thr Arg Ala Gly Asn Phe Arg Phe Thr Gln Asp Gly Phe Leu Asn Asp  
 105 110 115 120

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ser Leu Phe Ile Xaa Ala Asn Arg Tyr Glu Asn Pro \* Xaa Arg Xaa  
 1 5 10 15  
 Gly Thr Val Ser Asn Asn Ile Ala Asn Ala Asn Thr Ile Gly Tyr Lys  
 20 25 30  
 Gln Gln Gln Val Val Phe Gln Asp Leu Phe Ser Gln Asp Leu Ala Ile  
 35 40 45  
 Gly Phe Thr Gly Ser Gln Gly Pro Asn Gln Ala Gly Met Gly Ala Gln  
 50 55 60  
 Val Gly Ser Val Arg Thr Ile Phe Thr Gln Gly Ala Phe Glu Pro Gly  
 65 70 75 80  
 Asn Ser Val Thr Asp Pro Ala Ile Gly Gly Lys Gly Phe Phe Gln Val  
 85 90 95  
 Thr Leu Glu Asp Lys Val His Tyr Thr Arg Ala Gly Asn Phe Arg Phe  
 100 105 110  
 Thr Gln Asp Gly Phe Leu Asn Asp

- 53 -

115

120

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1450 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..414

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1083..1450

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GA TCT AAA GAG TCT ACA TAT ATT GCC CGA ATT GAA AAT TCT ACA AGT	47
Ser Lys Glu Ser Thr Tyr Ile Ala Arg Ile Glu Asn Ser Thr Ser	
1 5 10 15	
GAA AAA ACA CTA AAT GAT CTT GAT ATA CIT TTA AAA GAT GTG ATG TTA	95
Glu Lys Thr Leu Asn Asp Leu Asp Ile Leu Leu Lys Asp Val Met Leu	
20 25 30	
ACA TCA AAA AAG CAT GAA TCA CGT AGA CTT GCA GAG TCT GTA CAT CAA	143
Thr Ser Lys Lys His Glu Ser Arg Arg Leu Ala Glu Ser Val His Gln	
35 40 45	
AAT ATT CTT ACC CAC CTT ATA CAA AAA AAT TAT AAT ACT CAC AAT GGT	191

- 54 -

Asn Ile Leu Thr His Leu Ile Gln Lys Asn Tyr Asn Thr His Asn Gly	
50 55 60	
GGG ATA AAA TCT GCA CCT TTT CAT GTT CTT ATA GGA CCC AAA ATA CCA	239
Gly Ile Lys Ser Ala Pro Phe His Val Leu Ile Gly Pro Lys Ile Pro	
65 70 75	
AGT ATT CTT GTT GAA GTA GGT TAC TGT AGT AAT AAA GCT GAA GCA CAG	287
Ser Ile Leu Val Glu Val Gly Tyr Cys Ser Asn Lys Ala Glu Ala Gln	
80 85 90 95	
CGT CTG GCA TCT AGT AAT TAC CAA AAA GCA TTA ATA GAA GGA TTA GCT	335
Arg Leu Ala Ser Ser Asn Tyr Gln Lys Ala Leu Ile Glu Gly Leu Ala	
100 105 110	
AAA GGT ATT TTC TGT TAC CTA AAA AAA CTA CAT CAC CTT GAT ATT TAC	383
Lys Gly Ile Phe Cys Tyr Leu Lys Lys Leu His His Leu Asp Ile Tyr	
115 120 125	
TCT AGT TTT ATY CTA TCT AAT TGC ACT TAA T AGCTTGGACA ATTATTATAT	434
Ser Ser Phe Ile Leu Ser Asn Cys Thr *	
130 135	
GAAGGGTATC CATGTGAAGG TACCTGGTTA AGCTTTTAAA TGTA AAAAATT ATGCAACCAT	494
ACYTTATTCC TTCAGAGGAG CTTCAATTATG AAAGTAAAAA CTCTTTCCAT GGCTATTTTA	554
GCTTGTTTAT TAGTAGCTAA CAGTGCATTT TCGGCTGACT TCCCTATTGG TGTCTTTAAT	614
TCTCAATCCA TTGCCATGGA GAGTGAAGCA GCTAAGGCCG CTCAAAAAAA ATTACAATCA	674
GAATTTGGTA ATGAAAAAAC ACAACTTGAA AACAAGCAAA AGWTTGCMMA CAAAAGCTGA	734
TGATTTACAA GCTWAGTCAG CAGCTATGTY TAACCAAGCA CGTGAAGATA AACAAAGAGA	794
ATTTCTTGAA CTTCGTCGTA ATTTGGAAGA AAAATYTCGT GACTTTGCAA TACGTGTCGA	854

- 55 -

ACAAGCTGAA AACACATTAC GTCAATATNT AGCTGAACAA ATNTATNTTG CTGCTGAAAC	914
TATAGCAAAA AAGAAAGGGT TAACTTGTT TTGATAGTGT TAGGGAAGTG TAATGTACCT	974
TGAAAAAAT TTAGATATTA CAAAGAAATT YTTGAAGCCA TAAATGCTGC ATGGAAAAAA	1034
GGTGGAAGTA AACTTCCAGA GATGGCAAAC CGGAAAAAAT AACAG ATG CCC CAG TAT	1091
Met Pro Gln Tyr	
1	
AAA CTT TCA GAA ATT GCT AAA CTT TTA AAC TTA ACA TTA CAA GGT GAT	1139
Lys Leu Ser Glu Ile Ala Lys Leu Leu Asn Leu Thr Leu Gln Gly Asp	
5 10 15 20	
GAT ATT GAA GTT GTA GGC GTA AAT ACA CTT CAA GAT GCA TCA CCA AAT	1187
Asp Ile Glu Val Val Gly Val Asn Thr Leu Gln Asp Ala Ser Pro Asn	
25 30 35	
GAG ATA AGT TTT CTA GCA AAT GCT AAA TAT ATT CAC CAG CTT GTT TTG	1235
Glu Ile Ser Phe Leu Ala Asn Ala Lys Tyr Ile His Gln Leu Val Leu	
40 45 50	
TCA CAG GCT GGT GCT ATT ATT CTT TCA AAA GAA TAT GCT AGT CGT GTT	1283
Ser Gln Ala Gly Ala Ile Ile Leu Ser Lys Glu Tyr Ala Ser Arg Val	
55 60 65	
CCA CGA GCA CTA ATC AGT ACT GAA CCA TAT AGA GAT TTT GGT AGA GTT	1331
Pro Arg Ala Leu Ile Ser Thr Glu Pro Tyr Arg Asp Phe Gly Arg Val	
70 75 80	
CTT TCT TTA TTC TCT ATA CCT CAA GGA TGT TTT GAT GGT ATA AGT CAT	1379
Leu Ser Leu Phe Ser Ile Pro Gln Gly Cys Phe Asp Gly Ile Ser His	
85 90 95 100	
CAA GCT TAT ATA CAC CCT ACA GCA CAA GTC TCT AAA ACA GCT ACT ATC	1427
Gln Ala Tyr Ile His Pro Thr Ala Gln Val Ser Lys Thr Ala Thr Ile	
105 110 115	

- 56 -

TAT CCT TTn GTT TTT ATA GGA TC  
 Tyr Pro Xaa Val Phe Ile Gly  
 120

1450

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 137 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Ser Lys Glu Ser Thr Tyr Ile Ala Arg Ile Glu Asn Ser Thr Ser Glu  
 1 5 10 15

Lys Thr Leu Asn Asp Leu Asp Ile Leu Leu Lys Asp Val Met Leu Thr  
 20 25 30

Ser Lys Lys His Glu Ser Arg Arg Leu Ala Glu Ser Val His Gln Asn  
 35 40 45

Ile Leu Thr His Leu Ile Gln Lys Asn Tyr Asn Thr His Asn Gly Gly  
 50 55 60

Ile Lys Ser Ala Pro Phe His Val Leu Ile Gly Pro Lys Ile Pro Ser  
 65 70 75 80

Ile Leu Val Glu Val Gly Tyr Cys Ser Asn Lys Ala Glu Ala Gln Arg  
 85 90 95

Leu Ala Ser Ser Asn Tyr Gln Lys Ala Leu Ile Glu Gly Leu Ala Lys  
 100 105 110

Gly Ile Phe Cys Tyr Leu Lys Lys Leu His His Leu Asp Ile Tyr Ser

- 57 -

115                      120                      125

Ser Phe Ile Leu Ser Asn Cys Thr \*

130                      135

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Pro Gln Tyr Lys Leu Ser Glu Ile Ala Lys Leu Leu Asn Leu Thr Leu  
 1                      5                      10                      15

Gln Gly Asp Asp Ile Glu Val Val Gly Val Asn Thr Leu Gln Asp Ala  
                     20                      25                      30

Ser Pro Asn Glu Ile Ser Phe Leu Ala Asn Ala Lys Tyr Ile His Gln  
                     35                      40                      45

Leu Val Leu Ser Gln Ala Gly Ala Ile Ile Leu Ser Lys Glu Tyr Ala  
                     50                      55                      60

Ser Arg Val Pro Arg Ala Leu Ile Ser Thr Glu Pro Tyr Arg Asp Phe  
                     65                      70                      75                      80

Gly Arg Val Leu Ser Leu Phe Ser Ile Pro Gln Gly Cys Phe Asp Gly  
                     85                      90                      95

Ile Ser His Gln Ala Tyr Ile His Pro Thr Ala Gln Val Ser Lys Thr

- 58 -

100	105	110
Ala Thr Ile Tyr Pro	* Val Phe Ile Gly	
115	120	

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 559 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 3..557

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GA TCA AAG CCG CAT TTA CNG CAA GAG TTA GAA ATT GAA GTT TTG AAA	47
Ser Lys Pro His Leu Xaa Gln Glu Leu Glu Ile Glu Val Leu Lys	
1 5 10 15	
AAA GAA GAC TTT GGG CGT CAT ATT GTT AAA TTA TGC TGG AAA GGT TCT	95
Lys Glu Asp Phe Gly Arg His Ile Val Lys Leu Cys Trp Lys Gly Ser	
20 25 30	
TTA TCA AAT ATC TTT TTT TCC TAT GGG GAT ATC CCG CAC CCA CCT TAT	143
Leu Ser Asn Ile Phe Phe Ser Tyr Gly Asp Ile Pro His Pro Pro Tyr	
35 40 45	
ATA CAT CAA AGT AAT AAG GTT CAG GAT AAG GAA AGA TAT CNT ACN GTA	191



- 59 -

Ile His Gln Ser Asn Lys Val Gln Asp Lys Glu Arg Tyr Xaa Xaa Val	
50 55 60	
TAC TCT ATA TTA CAT AAN CTG GGT TCT GTA GCA GCT CCT ACA GCT GGA	239
Tyr Ser Ile Leu His Xaa Leu Gly Ser Val Ala Ala Pro Thr Ala Gly	
65 70 75	
TTA CNC TTT TCT GAA ACT AGC CGT NAT AAA TTA CAC AAA NAT GGT ATT	287
Leu Xaa Phe Ser Glu Thr Ser Arg Xaa Lys Leu His Lys Xaa Gly Ile	
80 85 90 95	
AGT TGG GCA TAA ATC CCT CTT CAC GTG GGA TAT GGA ACA TTC AGT CCC	335
Ser Trp Ala * Ile Pro Leu His Val Gly Tyr Gly Thr Phe Ser Pro	
100 105 110	
GTC CTC TGC AAT GAC ATC CCA AAA CAT CTT ATC CNT TCT GAG TTT GTT	383
Val Leu Cys Asn Asp Ile Pro Lys His Leu Ile Xaa Ser Glu Phe Val	
115 120 125	
CAC TTT CCT GAA ACT ACN TTT TCC ACT ATA TTA AAT GCA CGG TTT GCA	431
His Phe Pro Glu Thr Xaa Phe Ser Thr Ile Leu Asn Ala Arg Phe Ala	
130 135 140	
NGG GAA TAC CTA TGT TCT GCC ATA GGG GAC CCA CTG TTG TCC CCA CCA	479
Xaa Glu Tyr Leu Cys Ser Ala Ile Gly Asp Pro Leu Leu Ser Pro Pro	
145 150 155	
TTG GAN GGG TGT TAT CTT ACC CCT TTC GCC CGG GGT TCC CCT CCC CAA	527
Leu Xaa Gly Cys Tyr Leu Thr Pro Phe Ala Arg Gly Ser Pro Pro Gln	
160 165 170 175	
CCC TAT TCC ATT GNG TTT TCC TCT CAA ATT AT	559
Pro Tyr Ser Ile Xaa Phe Ser Ser Gln Ile	
180 185	

- 60 -

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 185 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Ser Lys Pro His Leu Xaa Gln Glu Leu Glu Ile Glu Val Leu Lys Lys
 1             5             10             15

Glu Asp Phe Gly Arg His Ile Val Lys Leu Cys Trp Lys Gly Ser Leu
          20             25             30

Ser Asn Ile Phe Phe Ser Tyr Gly Asp Ile Pro His Pro Pro Tyr Ile
          35             40             45

His Gln Ser Asn Lys Val Gln Asp Lys Glu Arg Tyr Xaa Xaa Val Tyr
          50             55             60

Ser Ile Leu His Xaa Leu Gly Ser Val Ala Ala Pro Thr Ala Gly Leu
          65             70             75             80

Xaa Phe Ser Glu Thr Ser Arg Xaa Lys Leu His Lys Xaa Gly Ile Ser
          85             90             95

Trp Ala * Ile Pro Leu His Val Gly Tyr Gly Thr Phe Ser Pro Val
          100            105            110

Leu Cys Asn Asp Ile Pro Lys His Leu Ile Xaa Ser Glu Phe Val His
          115            120            125

Phe Pro Glu Thr Xaa Phe Ser Thr Ile Leu Asn Ala Arg Phe Ala Xaa
          130            135            140

```

- 61 -

Glu Tyr Leu Cys Ser Ala Ile Gly Asp Pro Leu Leu Ser Pro Pro Leu  
 145                      150                      155                      160

Xaa Gly Cys Tyr Leu Thr Pro Phe Ala Arg Gly Ser Pro Pro Gln Pro  
                     165                      170                      175

Tyr Ser Ile Xaa Phe Ser Ser Gln Ile  
                     180                      185

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..294

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

T ATA AAA CAT TAG CGN CTT TNG TAT TTG GAC TTC AAA AAA ATT TTT	46
Ile Lys His * * Leu * Tyr Leu Asp Phe Lys Lys Ile Phe	
1                      5                      10                      15	
AAT TAT ATA GGA GAA CAT TCA CCA TTA AAA CGT AAT GTA ANT ATG GAA	94
Asn Tyr Ile Gly Glu His Ser Pro Leu Lys Arg Asn Val * Met Glu	
20                      25                      30	
GAT GTA GGT AAA TCT GCT GTT TTT TTA GCT TCA GAC CTN TCA TCA GGA	142
Asp Val Gly Lys Ser Ala Val Phe Leu Ala Ser Asp * Ser Ser Gly	

- 62 -

35	40	45	
GTA ACC GGT GAA TTN TTT TTG TTG ATG CTG GNA CAA TAA TTT AGG TAT			190
Val Thr Gly Glu * Phe Leu Leu Met Leu * Gln * Phe Arg Tyr			
50	55	60	
TTA ACC ATA CAT GCT TTA TAC AAC ATA TTG TGA GTT ACA ATA GCC ATA			238
Leu Thr Ile His Ala Leu Tyr Asn Ile Leu * Val Thr Ile Ala Ile			
65	70	75	
ACA CAT TTA TAT TCT ATA TAA TAA CAG TAG AAT AAT AAT AGA ATA TTT			286
Thr His Leu Tyr Ser Ile * * Gln * Asn Asn Asn Arg Ile Phe			
80	85	90	95
TTT ATG ACC ATTTGTATCT ATACAATAGT AAATAGATTA ATACATATAA GACTATATTC			344
Phe Met Thr			
TTTTTGAGAG CAACTTAAAG GAGCGGTTAT GGCTTTAGTT ACAAAGAAG AAGTACTTCA			404
ATACCATAGT GAACCCCGAC CAGGTAAACT TGAAGTATTT TCTATAAAAC CATGTAAAC			464
ACAAAAAGAT CC			477

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 97 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ile Lys His \* Xaa Leu Xaa Tyr Leu Asp Phe Lys Lys Ile Phe Asn

- 63 -

1                      5                      10                      15  
 Tyr Ile Gly Glu His Ser Pro Leu Lys Arg Asn Val Xaa Met Glu Asp  
                     20                      25                      30  
 Val Gly Lys Ser Ala Val Phe Leu Ala Ser Asp Xaa Ser Ser Gly Val  
                     35                      40                      45  
 Thr Gly Glu Xaa Phe Leu Leu Met Leu Xaa Gln \* Phe Arg Tyr Leu  
                     50                      55                      60  
 Thr Ile His Ala Leu Tyr Asn Ile Leu \* Val Thr Ile Ala Ile Thr  
                     65                      70                      75                      80  
 His Leu Tyr Ser Ile \* \* Gln \* Asn Asn Asn Arg Ile Phe Phe  
                     85                      90                      95  
 Met

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 525 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 2..525

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

- 64 -

G GAA TTG TTA GTA TTC TCC CAG AAC AGA AGC CAA AAT ATT TGG CTA	46
Glu Leu Leu Val Phe Ser Gln Asn Arg Ser Gln Asn Ile Trp Leu	
1 5 10 15	
CTT ACA TTA CCT ATT TTT GTG TTA GGT ATA GCA CAA GGT ATA TCA TTT	94
Leu Thr Leu Pro Ile Phe Val Leu Gly Ile Ala Gln Gly Ile Ser Phe	
20 25 30	
CCT TTA GTA AAC AGC CAC ATT ACA TCA CTT GCA CCA ACA TCC AAC AGA	142
Pro Leu Val Asn Ser His Ile Thr Ser Leu Ala Pro Thr Ser Asn Arg	
35 40 45	
GCT ATT GTT ATG GCT ATA AAC AGT ACA TTT ATG AGG TTA AGT CAG AGT	190
Ala Ile Val Met Ala Ile Asn Ser Thr Phe Met Arg Leu Ser Gln Ser	
50 55 60	
ATT TCG CAA ATG GTT TTT GGT ATT GGA TGG TCA TTT TTT GGT TGG CCT	238
Ile Ser Gln Met Val Phe Gly Ile Gly Trp Ser Phe Phe Gly Trp Pro	
65 70 75	
GGT CCT TTT ATA TTT GGT CTT TTT ACT TCT ATT ATA TTA GCC CTC TTA	286
Gly Pro Phe Ile Phe Gly Leu Phe Thr Ser Ile Ile Leu Ala Leu Leu	
80 85 90 95	
ATT ATG AAG TAT TTT CAA GAT GTA ACC CAA TAT CAC CTA TTT TTG ATA	334
Ile Met Lys Tyr Phe Gln Asp Val Thr Gln Tyr His Leu Phe Leu Ile	
100 105 110	
AGT AGT AAA TTT TAT TAT TAA AAA GCT TAG TTA GTT AAG ATT ACA TAT	382
Ser Ser Lys Phe Tyr Tyr * Lys Ala * Leu Val Lys Ile Thr Tyr	
115 120 125	
ATT ATA TAC AAT TAC TAT AAC ATT AAC TAA TTA CTA ACT ATT ACT TCC	430
Ile Ile Tyr Asn Tyr Tyr Asn Ile Asn * Leu Leu Thr Ile Thr Ser	
130 135 140	
AAT TGA TTA ATT GAT GCT ATT TAA AGA GGA TAT ATT AAT GAT GTC ATG	478

- 65 -

Asn \* Leu Ile Asp Ala Ile \* Arg Gly Tyr Ile Asn Asp Val Met  
 145 150 155

GCT CAC AAT AGG TGT TAT CCT TGG ATT AGT GCA TGG GAT CCA GGT CC 525  
 Ala His Asn Arg Cys Tyr Pro Trp Ile Ser Ala Trp Asp Pro Gly  
 160 165 170

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 174 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Glu Leu Leu Val Phe Ser Gln Asn Arg Ser Gln Asn Ile Trp Leu Leu  
 1 5 10 15  
 Thr Leu Pro Ile Phe Val Leu Gly Ile Ala Gln Gly Ile Ser Phe Pro  
 20 25 30  
 Leu Val Asn Ser His Ile Thr Ser Leu Ala Pro Thr Ser Asn Arg Ala  
 35 40 45  
 Ile Val Met Ala Ile Asn Ser Thr Phe Met Arg Leu Ser Gln Ser Ile  
 50 55 60  
 Ser Gln Met Val Phe Gly Ile Gly Trp Ser Phe Phe Gly Trp Pro Gly  
 65 70 75 80  
 Pro Phe Ile Phe Gly Leu Phe Thr Ser Ile Ile Leu Ala Leu Leu Ile  
 85 90 95

- 66 -

Met Lys Tyr Phe Gln Asp Val Thr Gln Tyr His Leu Phe Leu Ile Ser  
 100 105 110

Ser Lys Phe Tyr Tyr \* Lys Ala \* Leu Val Lys Ile Thr Tyr Ile  
 115 120 125

Ile Tyr Asn Tyr Tyr Asn Ile Asn \* Leu Leu Thr Ile Thr Ser Asn  
 130 135 140

\* Leu Ile Asp Ala Ile \* Arg Gly Tyr Ile Asn Asp Val Met Ala  
 145 150 155 160

His Asn Arg Cys Tyr Pro Trp Ile Ser Ala Trp Asp Pro Gly  
 165 170

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 846 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (iii) SEQUENCE DESCRIPTION: SEQ ID NO:17:

TATTTACTCG CGCGGCCGGG CGTCTTACAC AAATGGATCC CTTGCANTAA TCCAAGGATA	60
ACNCCTATTG TGANCCATGA ACATCATCAN NATATCCTCT TTANATAGCA TCNANNWNTC	120
AANNGGAATT AACAGTTACT ANNTAGTTAA TGTCATAGTA ATTGTCNATA ATATATGTAA	180
TCTTAACTAA CTAAGCTNNT TAATAATAAA ATTNACTACT TATCAANAAT AGGTGATATN	240
GGGTACATC TTGAAAATAC TTNCCATAAT TANGAGGGCT AATATAATNG AANTAAAAAG	300
ACCANATATA AAAGGACCAG GCCAACCAAA AAATGACCAT CCAATACCNA AAACAATTGG	360



- 67 -

CGAAAATACT CTGACTTAAC CTCANAAATG TACTGTTTAT AGCCATATCA ATAGCTCTGT	420
TGGATGTNGG NGCAATTGAT GTAATGTGGC TGTNTACTAN ANGAAATGAT NTACCTCGTG	480
CTATNCCTAN NACAANAATA NGTAATGTAA GTANCCNAAT ATCTGGGCTT TGTAATGGGA	540
GAATAATNNC AAGTCCTTGG GAAATNAANT TACNNCCAGC CAGCTATNNT AAGCAGTTCT	600
NTGGTGACTA TACGTCCTAC TNAANTCGTG CCAAAGATTA AATANNCGAT AATCGCNCNTN	660
CCTAAANCAN GCAATACTAA AATGGTTTCT NCCTANCTTG GNATANGGTG GAAGCNCGGA	720
CAGAATTNAN TTCGCNANTT TANANNGGAA NATNCGTNAA NTTANTCGGG GCCCANNCCN	780
AAATTCCTNA NTCNATANAN NAACTNNCTN CTNTAAAANG GCCNACTGGA NTNGTTAAAT	840
GAAATA	846

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 855 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GATNTTTTAT CGATCACTNT AGACGCGATT TGGGNAACAC TTACCTGGTA NCCACCCGGG	60
TGGAAAAATC GATGGGCCCC CGGCCGCTCT AGAAGTACTC TCGAGAAGCT TTTTGAATTC	120
TTTGATCCT CAACACAGGG TATGGATTAA AACAACTTTA GCTCTAACAG GAGCATTTTA	180
TAATATATTC CCTGGTAGAA CAATATCTAC TCAAGAAAAT CTGTCTATTG GTTTTCAACT	240
AAAAAAAATC TTAAACCTT TTCATTGGAC CATCTTACTC TTAGATGAAC ATTATATGTC	300
TTGCGCAAGA ATTGCAGCAG CAATTATGCC TGCACAGCTT GCTGGAGTTA AAAACATTAT	360

- 68 -

AGCTGTTTGG ACCAGTAAAA ATAACCGACT GACCGCTGAA AAAATCTCAC CTGCTTTACT	420
AACAACATTA GAACTTTCAG GAGTTAACAT AGCCCTAACA CTTACCCACA CTGAAACTGA	480
ACTTCTTATT CATCAATTAA TGAAAATAGG TATTGGAAAC CTGTTATATT TTTTAAAGA	540
AGAAGACATA CTACATATAT CTAATATACC TGTACTACCT TTCTGAAAG AATATACTTC	600
TCATCGACTT GTTATAGAAA AAGATGCTGG CNTTAATACA GAAATCCTCC AATGGGCNCA	660
TCCTCATTC AATTATTGAAC AAATAGCAAC AGAACCATAC TCTGAAANAT ATCCCAGATG	720
CAGTTTACTG TGCTAGCTCA TCCANTAAAA ACTATNCTCA TANAGNATCC CCAGAATTTT	780
TCATNATGGA CTTGAACCTA TTTGGATTCA NCCCAACNCT TCCTCCAANC CTCCTTTCTC	840
CATACACCAT GGGGA	855

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1082 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TATCTNGTTG ANTCAATAAA ACTTTTGGGG CCCNTNAAAN TTTCATNANN AAAAAACAA	60
NATTNCTGGG GGNCCNTCC CAAAAAANNC AATCANTNNG AANCTGNCT TCTTATTNNG	120
NTTTTNANAC TATAATATNT NTTATCNATA ATNNATCNNT ATACTNATTT CTNATTCANT	180
NACANNGGNN AGNAANNITA ATCTNAAANA CTNCNAAGGG GGNNTNATA NTNTTNTTTT	240
NTTNTCCCN TNNAATNNAT AACCNMNCAC CCNNATTANT TNNAATNNAT ACCATANCNN	300
CCTTTCAAAC TGTACACATA NTANNNAANN ACACTCNANC NTTTTNCATC CTCTCTANTN	360

- 69 -

CCNACTCCNA TNNANCTNTT CCCCCATNCC TATNTNTCNC TGCTTCCCAG NTTNNACNTN	420
NCTTNNTTTC ACANTATTCC TATCCAANCT AACATNTNTN NTNTCNTNCT CCTTNTNTNT	480
TATNTNTTTC TNNACCTNN CACTGACANT CTATNANTNA NNTCNNATAC TNNATANTCT	540
NTANGCNANT NTATCIANAA NTNTANCNNN NNATCNTNAC NGCCGTNNAT NTNNNNNCAN	600
TIANNIANN CTANCNTNNC CAANNNCNTA TNTATNAATA ACNACTATCC NATATTNNAT	660
TNNNTNTNT CNTANNCAAA TNATTTANGC NCACNNCACT ANGTNATATN ANNATTNTAT	720
ATTNTGAANC TTCTNGGCTT CNCNAATANT ACCANTNNNC ANCNTCNNNT NCATCTNNNT	780
NTACTTCNTA CCATANGCCT CTCNAGNNTC ACTACTTCTA NTAGTNATCN TCTACTGCCN	840
ATGGCMMNNN GCNNNNCGAN AGNTATNCAC NTACANTNNC NTCTACTATN TANATCTANN	900
NCNTCCGNNG CCTNCGTAC GNNTNGGCNA ANTCGNNTAC TTTNCNTNTA TCTAGTCNCA	960
TCAGNNNTNG ANTCCTCAAN CNNGCTCTAN TTACATGTNN MNTNATGCNC TANANCGNNA	1020
CNTCTATCCT TCNANTCTGC NCTNANTNTA TANACTCTNN MNNATCNNCN AANCTATNTC	1080
CC	1082

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 354 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (iii) SEQUENCE DESCRIPTION: SEQ ID NO:20

CTCCNTNMC NCTAAGTGGA NTCGCGCGCT GCAGGTCGAC ACTAGTGGAT CTTGATATAC	60
TTTAAAGA TGTGATGTTA ACATCAAAA AGCATGAATC ACGTTAGACT TGCAGAGTCT	120
GTACATCAA ATATTCTTTA CCCACCTTAA TACGAAAANA AATNNTTATN CNCCNCNATG	180
GGTGGGGNTN AAATCCTNGC CCCNTNCCC TGTCNTTTA GGGAACCCCC NAATTCCCN	240
NGTTATTCCT CTGTTTGAAA NTTCTGGTTN CCCGGCCCTN TNACCAANAG CTTGANNNCC	300
NCCCCGTCCT GGGGCATCCT CNTGTTTATT TTCCTCNAN CNCCCCCTTN ACTN	354

- 70 -

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (iii) SEQUENCE DESCRIPTION: SEQ ID NO:21

GGATCTTTTT GTGTTTTACA TGGTTTTATA GGAAATACTT CAAGTTTACC TGGTCGGGGT	60
TCACTATGGT ATTGAAGTAC TTCTTCITTT GTNACTAAAG CCATAACCGC TCCTTTAAGT	120
TGTTCTCAA AAGAATATAG TCTTATATGT ATTAATCTAT TTACTATTGT ATAGATACAA	180
TAGGTCATAA AAAATATTCT ATTATTATTC TACTGTTATT ATATAGAATA TAAATGTGTT	240
ATGGCTATTG TAACTCACAA TATGTTGTAT AAAGCATGTA TGGTTAAATA CCTAAATTAT	300
TGYNCCAGCA TCAACAAAAA NAATTCACCG GTTACTCCTG ATGANAGGTC TGAAGCTAAA	360
AAAACAGCAG ATTTACCTAC ATCTCCATA NTTACATTAC GTTTTAATGG TGAATGTTCT	420
CCTATATAAT TAAAAATTTT TTTGAAGTCC AAATACNAAA GNCGCTAATG TTTTATA	477

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 568 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (iii) SEQUENCE DESCRIPTION: SEQ ID NO:22

- 71 -

GATCATTAA AAAACCATCT TGAGTAAAC GAAAATCCC TGCTCGTGA TAGTGTACTT	60
TATCCTCTAA TGTAACCTGA AAAAAACCTT TTCCACCAAT AGCAAGATCT GTTACACTAT	120
TGCCAGGTTT AAAAGCACCC TGTGTAAAA TTGTGCGAAC ACTTCCAACC TGTGCTCCCA	180
TACCAGCCTG GTTTGGCCCC TGACTTCCAG TAAAACCTAT TGCTAAATCT TGACTAAACA	240
GGTCTTGAAA CACTACCTGT TGCTGCTTAT ACCCAATGGT ATTTGCGTTA GCAATATTAT	300
TGGAGACAGT ACCANCCCTG TNCTATGGGT TTTCATACCT GTTGGCANCA ATAAACAAAC	360
TCCCCATCAT GATAACATCT CCTAAAAAT AATTTTCATGG NGGNAAAAAT GTTACCTACA	420
CATCTCTATT TTNAAAGCAA AAAACCCATG CCCAANAAAA TTTTGGGCC NAATTAATAT	480
ACTTAATCTA ATAACTTTT TTGGGTAATN AAAAAAAT AATTTTTTAA ACTTGTTTN	540
ACCAACCTTT TCTCCTTACT TTTTAACC	

- 72 -

## (2) INFORMATION FOR SEQ ID NO:23:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 477 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (iii) SEQUENCE DESCRIPTION: SEQ ID NO:23

GGTACCCAC CCGGGTGGAA AATCGATGGG CCGCGGCCG CTCTAAAANT	50
ACTCTCGAGA AGCTTTTGA ATTCITTGGA TCCCAGGAA TAACTTGTTG	100
ACGGAATTTT ACATTTTCTA TCCCTGCAA TANAAAACT TTACCTTGTA	150
GTTCAATTAAT AGGAAAAGAT TGGAGTACTG TGATTCCACC TGATTGCGCC	200
ATAGCTTCTA AAATTAGAAC TCCAGGCATG ACAGGAAATC CAGGGGAAAT	250
GACCCNGAAA AAATGGTTCA TTAATACTAA CATTTTATA AGCTTTAATA	300
TATTTGCCAG CATTAATTC AATAACTCTA TCTACAATTA AAAAGGGATA	350
ACGGTGGGGA ATTTACTGTA AAATTTCTTG GATATTTTGG AGGTATGGAT	400
GGGGACATTA ATTTTCCTAT ATATATGCTC TTTTCTTTT CNAAAATTTT	450
TCAGCTTTT TATCCNTAA AAACCTC	467

## CLAIMS:

1. A vaccine composition for the prophylaxis or treatment of infection in an animal or bird by *Lawsonia intracellularis* or related microorganism, said vaccine composition comprising an immunogenic, non-pathogenic form of *L. intracellularis* or related microorganism or an immunogenic component thereof and one or more carriers, diluents and/or adjuvants suitable for veterinary or pharmaceutical use.
2. A vaccine composition according to claim 1 wherein the composition is for the prophylaxis or treatment of infection in pigs by *L. intracellularis* or related microorganism.
3. A vaccine composition according to claim 2 wherein the non-pathogenic form of *L. intracellularis* or related microorganism is an attenuated strain of the microorganism.
4. A vaccine composition according to claim 2 wherein the non-pathogenic form of *L. intracellularis* or related microorganism is a killed preparation of the microorganism.
5. A vaccine composition according to claim 4 wherein the non-pathogenic form of *L. intracellularis* is a formalin-killed preparation of the microorganism.
6. A vaccine composition according to claim 1 or 2 wherein said composition comprises a peptide, polypeptide, protein, carbohydrate, lipid or nucleic acid molecule or a combination thereof from *L. intracellularis* or related microorganism in an amount effective to induce a protective immune response agent *L. intracellularis* or related microorganism.
7. A vaccine composition according to claim 6 wherein the composition comprises a peptide, polypeptide, protein or a derivative thereof from *L. intracellularis* or related microorganism.

- 74 -

8. A vaccine composition according to claim 7 wherein the peptide, polypeptide or protein is in recombinant form.
9. A vaccine composition according to claim 7 or 8 wherein the composition comprises a refolding/heatshock protein, a flagellar basal body rod protein, S-adenosylmethionine: tRNA ribosyltransferase-isomerase, autolysin, enoyl-(acyl-carrier-protein) reductase or a glucarate transporter or derivative thereof.
10. A vaccine composition according to claim 9 wherein the protein is GroEL having an amino acid sequence set forth in SEQ ID NO:2 or is a protein having at least about 40% similarity thereto.
11. A vaccine composition according to claim 9 wherein the protein is GroES having an amino acid sequence set forth in SEQ ID NO:4 or is a protein having at least about 40% similarity thereto.
12. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:1 or a sequence having at least about 40% similarity thereto.
13. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:3 or a sequence having at least about 40% similarity thereto.
14. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:5 or a sequence having at least about 40% similarity thereto.
15. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:6



or a sequence having at least about 40% similarity thereto.

16. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:8 or a sequence having at least about 40% similarity thereto.

17. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:11 or a sequence having at least about 40% similarity thereto.

18. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:13 or a sequence having at least about 40% similarity thereto.

19. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:15 or a sequence having at least about 40% similarity thereto.

20. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:17 or a sequence having at least about 40% similarity thereto.

21. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:18 or a sequence having at least about 40% similarity thereto.

22. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:19 or a sequence having at least about 40% similarity thereto.

- 76 -

23. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:20 or a sequence having at least about 40% similarity thereto.
24. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:21 or a sequence having at least about 40% similarity thereto.
25. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:22 or a sequence having at least about 40% similarity thereto.
26. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:7 or a sequence having at least 40% similarity.
27. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:9 or a sequence having at least 40% similarity.
28. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:10 or a sequence having at least 40% similarity.
29. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:12 or a sequence having at least 40% similarity.
30. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:14 or a

sequence having at least 40% similarity.

31. A vaccine composition according to claim 8 wherein the composition comprises a peptide, polypeptide or protein having an amino acid sequence of SEQ ID NO:16 or a sequence having at least 40% similarity.

32. A method for vaccinating an animal or bird against infection by *L. intracellularis* or related microorganism or treating an animal or bird infected by *L. intracellularis*, said method comprising administering to said animal or bird an effective amount of a non-pathogenic form of *L. intracellularis* or related microorganism or an immunogenic component thereof for a time and under conditions sufficient to induce a protective immune response against *L. intracellularis* or related microorganism.

33. A method according to claim 32 wherein the animal is a pig.

34. A method according to claim 33 wherein the non-pathogenic form of *L. intracellularis* or related microorganism is an attenuated strain of the microorganism.

35. A method according to claim 33 wherein the non-pathogenic form of *L. intracellularis* or related microorganism is a killed preparation of the microorganism.

36. A method according to claim 35 wherein the non-pathogenic form of *L. intracellularis* is a formalin-killed preparation of the microorganism.

37. A method according to claim 32 and 33 wherein said immunogenic component comprises a peptide, polypeptide, protein, carbohydrate, lipid or nucleic acid molecule or a combination thereof from *L. intracellularis* or related microorganism in an amount effective to induce a protective immune response against *L. intracellularis* or related microorganism.

38. A method according to claim 37 wherein said immunogenic component comprises a

- 78 -

peptide, polypeptide, protein or a derivative thereof from *L. intracellularis* or related microorganism.

39. A method according to claim 38 wherein the peptide, polypeptide or protein is in recombinant form.

40. A method according to claim 29 or 30 wherein the immunogenic component is a refolding/heatshock protein, a flagellar basal body rod protein, S-adenosylmethionine: tRNA ribosyltransferase-isomerase, autolysin, enoyl-(acyl-carrier-protein) reductase or a glucarate transporter or derivative thereof.

41. A method according to claim 40 wherein the protein is GroEL having an amino acid sequence set forth in SEQ ID NO:2 or is a protein having at least about 40% similarity thereto.

42. A method according to claim 40 wherein the protein is GroES having an amino acid sequence set forth in SEQ ID NO:4 or is a protein having at least about 40% similarity thereto.

43. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:1 or a sequence having at least about 40% similarity thereto.

44. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:3 or a sequence having at least about 40% similarity thereto.

45. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:5 or a sequence having at least about 40% similarity thereto.

46. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:6 or a sequence having at least about 40% similarity thereto.
47. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:8 or a sequence having at least about 40% similarity thereto.
48. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:11 or a sequence having at least about 40% similarity thereto.
49. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:13 or a sequence having at least about 40% similarity thereto.
50. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:15 or a sequence having at least about 40% similarity thereto.
51. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:17 or a sequence having at least about 40% similarity thereto.
52. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:18 or a sequence having at least about 40% similarity thereto.
53. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:19

or a sequence having at least about 40% similarity thereto.

54. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:20 or a sequence having at least about 40% similarity thereto.

55. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:21 or a sequence having at least about 40% similarity thereto.

56. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein encoded by a nucleotide sequence comprising SEQ ID NO:22 or a sequence having at least about 40% similarity thereto.

57. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:7 or having at least 40% similarity thereto.

58. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:9 or having at least 40% similarity thereto.

59. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:10 or having at least 40% similarity thereto.

60. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:12 or having at least 40% similarity thereto.

61. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:14 or having at least 40% similarity thereto.
62. A method according to claim 38 wherein the immunogenic component comprises a peptide, polypeptide or protein comprising an amino acid sequence set forth in SEQ ID NO:16 or having at least 40% similarity thereto.
63. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:1 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:1 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.
64. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:3 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:3 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.
65. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:5 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:5 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.
66. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:6 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:6 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein

from *L. intracellularis* or related microorganism.

67. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:8 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:8 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

68. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:11 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:11 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

69. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:13 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:13 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

70. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:15 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:15 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

71. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:17 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:17 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein



from *L. intracellularis* or related microorganism.

72. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:18 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:18 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

73. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:19 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:19 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

74. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:20 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:20 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

75. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:21 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:21 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein from *L. intracellularis* or related microorganism.

76. An isolated nucleic acid molecule comprising a nucleotide sequence as set forth in SEQ ID NO:22 or a nucleotide sequence having at least 40% similarity to the nucleotide sequence set forth in SEQ ID NO:22 and which is capable of hybridizing thereto under low stringency conditions and which encodes an immunogenic peptide, polypeptide or protein

from *L. intracellularis* or related microorganism.

77. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:1 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:1 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

78. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:3 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:3 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

79. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:5 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:5 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

80. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:6 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:6 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

81. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:8 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:8 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective

immune response against *L. intracellularis* or related microorganism.

82. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:11 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:11 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

83. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:13 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:13 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

84. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:15 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:15 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

85. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:17 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:17 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, ~~polypeptide or protein effective to induce a~~ protective immune response against *L. intracellularis* or related microorganism.

86. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:18 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:18 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a

protective immune response against *L. intracellularis* or related microorganism.

87. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:19 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:19 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.


88. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:20 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:20 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

89. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:21 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:21 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

90. A genetic vaccine comprising a DNA sequence having a nucleotide sequence set forth in SEQ ID NO:22 or having at least 40% similarity thereto or is capable of hybridizing to SEQ ID NO:22 under low stringency conditions, said DNA sequence capable of expression in a pig to produce an amount of a peptide, polypeptide or protein effective to induce a protective immune response against *L. intracellularis* or related microorganism.

1/4

395 Y10 Y12 Y14 Y16

FIG 1

2/4



FIG 2

SUBSTITUTE SHEET (RULE 26)

3/4




FIG 3

4/4



FIG 4



# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/AU 96/00767

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int Cl <sup>8</sup> : C12N 15/31, A61K 39/02, A61K 39/106		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) IPC C12N 15/31, A61K 39/02, A61K 39/106		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched AU:IPC (as above)		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent, Chemical Abstracts: lawsonia, intracellularis, ilcal, groel, groes, chaperonin STN: nucleotide/amino-acid search.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AU, 69290/94, A (Institut Pasteur et al.) 12 December 1994	1, 2, 6, 7, 10, 11, 63, 64, 77, 78
X	Suerbaum et al., "Helicobacter pylori hspA-hspB heat-shock gene cluster: nucleotide sequence, expression putative function and immunogenicity", Molecular Microbiology, Vol. 14, No. 5, 1994, pages 959-974, see entire document.	1, 2, 6, 7, 10, 11, 63, 64, 77, 78
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 13 February 1997		Date of mailing of the international search report 26 FEB 1997
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (06) 285 3929		Authorized officer  R.L. POOLEY Telephone No.: (06) 283 2242

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/AU 96/00767

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Kansau et al., "Heat shock proteins of <i>Helicobacter pylori</i> ", Aliment. Pharmacol. Ther., Vol. 10, Suppl. 1, 1996, pages 51-6, see entire document.	1, 2, 6, 7, 10, 11, 63, 64, 77, 78
X	Wu et al., "Heat Shock- and Alkaline pH-Induced Proteins of <i>Campylobacter jejuni</i> : Characterization and Immunological Properties", Infection and Immunity, Vol. 62, No. 10, 1994, pages 4256-4260, see entire document.	1, 2, 6, 7, 10, 11, 63, 64, 77, 78
X	Dunn et al., "Identification and Purification of a cpn 60 Heat shock Protein Homolog from <i>Helicobacter pylori</i> ", Infection and Immunity, Vol. 60, No. 5, 1992, pages 1946-1951, see entire document.	63, 77
X	Evans et al., "Urease-Associated Heat Shock Protein of <i>Helicobacter pylori</i> ", Infection and Immunity, Vol. 60, No 5, 1992, pages 2125-2127, see entire document.	63, 77
X	Takata et al., "The Purification of a GroEL-Like Stress Protein from Aerobically Adapted <i>Campylobacter jejuni</i> ", Microbiol. Immunol., Vol. 39, No. 9, pages 639-645, see entire document.	63, 77
X	Bukanov et al., "Ordered cosmid library and high-resolution physical-genetic map of <i>Helicobacter pylori</i> strain NCTC11638", Molecular Microbiology, Vol. 11, No. 3, 1994, pages 509-523.	63, 77

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No.  
PCT/AU 96/00767

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member		
AU, A	69290/94	WO, 94/26901	EP, 703981	CA, 2144307	
		JP, 8510120			
END OF ANNEX					

**THIS PAGE BLANK (USPTO)**